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ABSTRACT 
The ability to produce genetically superior livestock has established somatic cell 
nuclear transfer (SCNT) as an invaluable tool in commercial livestock production. 
Successful reprogramming of somatic cells towards pluripotency requires the epigenetic 
marks characteristic of the differentiated cell type first be erased in order to inactivate 
the somatic cell program and activate the embryonic program.  Several small molecules 
have been shown to improve both the kinetics and efficiency of reprogramming.  These 
chemical modifiers aid in overcoming the “roadblocks” encountered during the 
reprogramming process by inducing the necessary epigenetic modifications needed to 
silence the somatic cell genome and completely reactivate the embryonic stem cell 
(ESC) genome. If small molecules are used to “prime” the somatic cells to be used as 
donor cells in SCNT, the efficiency of nuclear reprogramming during SCNT may be 
enhanced. 
We first assessed the effect of pre-treatment with small molecules on the 
expression of Oct-4, Nanog, and Sox-2 in bovine fetal fibroblast (BFF) cells.  Chemical 
treatment consisted of 3 small molecules: PD0325901, a mitogen activated protein 
kinase/ERK kinase (MEK) inhibitor; CHIR99021, a glycogen synthase kinase-3 (GSK3) 
inhibitor; and NuP0178, a G9a histone methyltransferase inhibitor.  No significant 
difference in transcript levels for Oct-4, Nanog, or Sox-2 was detected, indicating that 
this combination of small molecule inhibitors does not have an effect on the expression 
of Oct-4, Nanog, and Sox-2 in BFF cells.   
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We next sought to assess the effects this combination of small molecule 
inhibitors has on the epigenetic state of Oct-4, Nanog, and Sox-2 in BFF cells. 
Chromatin Immunoprecipitation was used to quantify the enrichment of key histone 
modifications on the promoter regions of Oct-4, Nanog, and Sox-3 in BFF cells treated 
with and without PD0325901, CHIR99021, and NuP0178 over time.  Time, treatment, 
and a time*treatment interaction were found to have a significant effect on the histone 
modifications analyzed.  Determining how the expression of these factors alters the 
epigenetic marks in the promoter regions of key pluripotency-associated genes will 
allow for the development of defined conditions which best mimic the epigenetic 
landscape of ESC, ultimately leading to engineering the ideal donor cell for successful 
SCNT.   
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CHAPTER I 
INTRODUCTION 
 
In 2006, Takahashi and Yamanaka reported the generation of a population of 
cells similar to embryonic stem cells (ESC) by transfecting mouse tail fibroblast cells 
with four transcription factor-encoding genes.  These cells, termed induced pluripotent 
stem cells (iPSC), are morphologically similar to pluripotent ESC and, most importantly, 
demonstrate key characteristics of pluripotent ESC, including expressing stem cell 
markers, forming teratomas containing cells of all three germ layers, and contributing to 
multiple cell lineages (Takahashi and Yamanaka, 2006).  This landmark discovery 
paved the way for a rapidly progressing field of research.   
The resetting of the somatic cell nucleus to an embryonic state involves several 
complex mechanisms.  The expression of Oct-4, Nanog, Sox-2 and other pluripotency-
associated genes is silenced through the differentiation-induced actions of DNA 
methylation, histone deacetylation and histone methylation. These repressive 
mechanisms that function to silence the embryonic program must be overcome during 
reprogramming (Hochedlinger and Plath, 2009).  These key developmental genes 
contain bivalent domains consisting of both inhibitory H3K27 methylation marks and 
activating H3K4 methylation marks.  These bivalent domains are lost upon cellular 
differentiation, indicating that they play an important role in maintaining pluripotency.  In 
addition, epigenetic silencing associated with H3K9 methylation also contributes to the 
maintenance of pluripotency in ESC.  H3K9me3 is associated with repressive 
chromatin, and is maintained at low levels in ESC  (Bernstein et al., 2006).  These 
marks are a key feature in the epigenetic signature of ESC.   
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 Studies have revealed that epigenetics play a crucial role in nuclear 
reprogramming.  Resistance to reprogramming is largely attributed to the phenomenon 
of epigenetic memory that cells retain throughout numerous cell divisions.  As cells 
become more differentiated, they acquire epigenetic marks that make their nuclei 
increasingly resistant to reprogramming (Pasque et al., 2011).  However, modulations of 
the epigenetic processes that accompany nuclear reprogramming may facilitate the 
conversion to an epigenetic landscape that is more permissive to reprogramming.  
Various tools have been employed to help cells overcome this reprogramming 
roadblock, including the use of synthetic chemical epigenetic modulators known 
collectively as “small molecules”.  Several chemical compounds that control epigenetic 
enzymes, such as HDAC, HMT, DNMT, and histone demethylase (HDM) have been 
shown to improve reprogramming efficiency, or even replace the need to use certain 
transcription factors (Zhang et al., 2012).  This is especially promising for the clinical 
application of iPSC as there are serious concerns regarding the safety of current 
genetic approaches to nuclear reprogramming, as well as traditional culture systems 
that are used to maintain iPSC.  Small molecules provide an attractive approach to 
addressing these challenges, as they offer a number of compelling advantages.  First, 
the biological effects of small molecules are typically rapid, reversible and dose-
dependent, allowing precise control over specific outcomes by fine-tuning their 
concentrations and combinations. Second, the structural diversity that can be provided 
by synthetic chemistry allows the functional optimization of small molecules. Third, 
compared with genetic interventions, the relative ease of the handling and 
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administration of small molecules make them more practical for in vitro and in vivo 
applications, and for further therapeutic development (Zhang et al., 2012).   
Once established, cellular identity is remarkably stable.  Chromatin modifications 
are faithfully inherited from cell division to cell division, highlighting the major hurdles 
iPSC must overcome in order to be fully reprogrammed to pluripotency.  The use of 
small molecule compounds that target chromatin modifications and/or specific signaling 
pathways have proven to be effective at overcoming these reprogramming hurdles.  In 
the present study, we sought to assess the genetic and epigenetic effects pre-treatment 
with a small molecule cocktail have on BFF cells.   
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CHAPTER II 
LITERATURE REVIEW 
 
The History of Nuclear Reprogramming 
 
 In 2006, Takahashi and Yamanaka reported the generation of a population of 
cells similar to ESC by transfecting mouse tail fibroblast cells with four transcription 
factor-encoding genes.  These cells, termed induced pluripotent stem cells (iPSC), are 
believed to be immensely beneficial in the study and treatment of disease as the direct 
reprogramming of somatic cells provides an opportunity to generate patient- or disease-
specific pluripotent stem cells (Nakagawa et al., 2008).  The supposed potential of iPSC 
lies in the fact that these cells are morphologically similar to pluripotent ESC and, most 
importantly, demonstrate key characteristics of pluripotent ESC, including expressing 
stem cell markers, forming teratomas containing cells of all three germ layers, and 
contributing to multiple cell lineages (Takahashi and Yamanaka, 2006).  This landmark 
discovery has opened a new frontier in the field of regenerative medicine because, for 
the first time, a realistic way of generating sufficient numbers of patient-specific 
pluripotent stem cells exists (Amabile and Meissner, 2009).  Furthermore, this method 
of generating iPSC has provided researchers with a new and unique tool to study 
mammalian development and the mechanisms underlying nuclear reprogramming.   
 The breakthrough discovery that lineage-restricted somatic cells can be 
reprogrammed to a pluripotent state through the ectopic expression of defined 
transcription factors represents the culmination of over 50 years of research.   The 
history of nuclear reprogramming begins in 1952 with Briggs and King.  The long-
standing question of whether the process of development and cell differentiation 
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irreversibly alters the genome prompted Briggs and King (1952) to develop a system to 
directly test the genetic equivalence of somatic cell nuclei and embryonic cell nuclei.  In 
this first published nuclear transfer study, Briggs and King (1952) reported generating 
cloned frogs by transferring nuclei isolated from late-stage embryos into enucleated 
oocytes.  This work, together with seminal studies by Gurdon (1962; Gurdon et al., 
1975), provided the first conclusive evidence that genes of somatic cells are not 
irreversibly changed during differentiation.  Furthermore, these studies demonstrated 
the ability of the oocyte cytoplasm to facilitate the de-differentiation of the somatic cell 
nuclei in order to reset the developmental program (Briggs and King, 1952; Gurdon, 
1962; Gurdon et al., 1975).   
 Despite the early success of nuclear transplantation in frogs, it was not until 1997 
that the first mammal was successfully cloned using somatic cell nuclear transfer 
(SCNT). The birth of “Dolly”, a cloned sheep produced by fusing a mammary cell that 
had been induced to enter a quiescent state with an enucleated oocyte (Wilmut et al., 
1997), marks one of the most celebrated events in the history of biological research.  
Heralded by Science magazine as “the breakthrough of 1997”, “Dolly” decisively proved 
that even a fully differentiated mammalian somatic cell can be reverted to an embryonic 
state when transferred into an enucleated oocyte (Wilmut et al., 1997).  In spite of a 45 
year gap between the first nuclear transfer experiment by Briggs and King (1952) and 
the birth of “Dolly”, many key discoveries in the field of nuclear reprogramming were 
made during this 45 year period, including the development of different techniques that 
allowed researchers to derive, culture and study pluripotent cell lines.  Scientists’ 
earliest insight into the nature of pluripotent cells came from studying embryonal 
6 
 
carcinoma cells (ECC).  Derived from germ cell tumors known as teratocarcinomas, 
researchers discovered that ECC could be clonally expanded in culture while remaining 
pluripotent (Finch and Ephrussi, 1967).  The establishment of these immortal pluripotent 
cell lines marks a key event in the history of nuclear reprogramming because it provided 
scientists with a tool to explore the regulatory mechanisms underlying pluripotency.  
Among these scientists were Miller and Ruddle, who showed that the hybrid cells 
resulting from the fusion of murine teratocarcinoma cells and thymus cells adopted the 
biochemical and development properties of their ECC parent (Miller and Ruddle, 1976).  
The dominance of the pluripotent state over that of the somatic cell suggested that gene 
expression is not only regulated by cis-acting DNA elements but also by trans-acting 
factors present in ECC that confer pluripotency in somatic cells upon fusion (Stadtfeld 
and Hochedlinger, 2010).  Short-lived, non-dividing, multinucleate fusion products of two 
distinct cell types, known as heterokaryons provided the first definitive evidence that 
previously silent genes typical of diverse differentiated mammalian cells could be 
activated in other differentiated cell types (Blau et al., 1983).  Because a proliferating 
population of hybrid cells often results in nuclear fusion, loss and rearrangement of 
chromosomes, gene activation as a result of nuclear reprogramming cannot accurately 
be assessed.  Heterokaryons, on the other hand, do not divide; therefore, the nuclei of 
the two cells remain distinct and intact (Yamanaka and Blau, 2010).  In the first 
heterokaryon study, human amniotic cells and murine muscle cells were fused together 
to form heterokaryons that expressed several muscle proteins, indicating that muscle 
genes had been activated in non-muscle cells (Blau et al., 1983).  The belief that 
previously silent genes could be activated in muscle-cell-containing heterokaryons was 
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corroborated by other groups soon after (Wright, 1984), and it quickly became apparent 
that this was true for other cell types as well.   
 The results of these heterokaryon experiments lead researchers to the make the 
same conclusion about mammalian somatic cells as Briggs and King (1952) and 
Gurdon (1962; Gurdon et al., 1975) did about amphibian somatic cells years before: the 
differentiated state of somatic cells is not fixed and irreversible.  Instead, these 
experiments illustrated that the generally stable state of differentiated somatic cells can 
be altered in response to changes in the cells’ environment, lending support to the 
theory of cellular plasticity.  Researchers hypothesized that the differentiated state of 
somatic cells is dictated by the balance of regulators and requires continuous 
regulation.   Alterations in the cells’ environment induce perturbations in the 
stoichiometry of these regulators, allowing the fate of somatic cells to change (Blau et 
al., 1983).   These observations prompted researchers to further investigate the 
regulators responsible for maintaining the differentiated state of somatic cells and how 
changes in the levels of these regulators in the cell can alter cell fate.  In 1987, 
Schneuwly et al. demonstrated that the overexpression of a D. melanogaster homeotic 
gene, Antennapedia, under the control of a heat-shock gene promoter led to the 
formation of an additional set of legs instead of an antenna.  Around the same time, the 
first mammalian master regulatory transcription factor, MYOD, was identified. Davis et 
al. (1987)reported the formation of myofibers in murine fibroblast cell lines transduced 
with retroviral vectors expressing the skeletal muscle transcription factor MYOD, 
demonstrating that overexpression of this single transcription factor is sufficient to 
convert fibroblast to myoblast.  These studies demonstrated that lineage-associated 
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transcription factors-which help to establish and maintain cellular identity during 
development by driving the expression of cell type-specific genes while suppressing 
lineage-inappropriate genes-can change cell fate when ectopically expressed in certain 
heterologous cells (Stadtfeld and Hochedlinger, 2010).  Importantly, these studies 
prompted a more systematic search for transcription factors that could induce the 
conversion of differentiated cells to a pluripotent state.  Almost 20 years later, these 
factors were identified (Takahashi and Yamanaka, 2006).   
Nuclear Reprogramming Strategies 
 Each of the aforementioned experiments represents a major milestone in the 
history of nuclear reprogramming.  These key discoveries have impacted the field of 
nuclear reprogramming by providing scientists’ not only with a better understanding of 
the mechanisms underlying the process of nuclear reprogramming but also with the 
conceptual framework needed for the development of current reprogramming 
techniques.  Currently, there are four methods of reprogramming differentiated somatic 
cells to a pluripotent state: SCNT (Wilmut et al., 1997), fusion with ESC (Cowan et al., 
2005), exposure to ESC extracts (Bru et al., 2008), introduction of defined factors 
(Takahashi and Yamanaka, 2006).   
Somatic Cell Nuclear Transfer 
 In 1997, Wilmut and colleagues introduced the world to “Dolly”, the first 
successfully cloned mammal from an adult cell.  By fusing a mammary epithelial cell 
from a Finn Dorset ewe with an enucleated donor oocyte, Wilmut et al (1997) 
unknowingly created “the world’s most famous sheep”.  Since the birth of “Dolly”, a wide 
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range of species have been successfully cloned using SCNT, including domesticated 
animals such as the cow (Kato et al., 1998) and dog (Lee et al., 2005), as well as wild 
animals like the African wildcat (Gomez et al., 2004) and wolf (Kim et al., 2007).   
 Wilmut and colleagues succeeded at what had been deemed for many years as 
“biologically impossible”.  The birth of “Dolly”, however, provided clearly convincing 
evidence that the nucleus of even fully differentiated mammalian cells can be 
reprogrammed to an embryonic state when transferred into enucleated oocytes (Wilmut 
et al., 1997).  Wilmut and colleagues succeeded at what others had been attempting for 
years by implementing cell cycle synchronization into their strategy.  They theorized that 
inducing the donor cells to exit the cell cycle by serum deprivation would change the 
chromatin structure in such a way that was conducive to nuclear reprogramming.   
Under normal conditions in vivo, high levels of Maturation Promoting Factor (MPF) 
found in the cytoplasm of metaphase II (MII) oocytes induce nuclear envelope 
breakdown and chromosome condensation to facilitate entry into the M phase of the cell 
cycle.   The activity of MPF can have beneficial or harmful effects upon the 
reconstructed embryo depending on the cell cycle stage of the donor cell (Campbell et 
al., 1993; Fulka et al., 1998).  High levels of MPF in the MII oocyte cause nuclear 
envelope breakdown and chromosome condensation in the transferred nucleus, 
irrespective of cell cycle stage of the donor cell.  If the nucleus is in S or G2 phase, then 
the potential for reduplication of the genome directed by the recipient cytoplasm will 
result in aberrant development (Hanocq-Quertier et al., 1976; Sunkara et al., 1979; 
Campbell et al., 1996; Kikyo and Wolffe, 2000).  If DNA synthesis is not yet complete, 
initiation of premature nuclear envelope breakdown and chromosome condensation will 
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lead to chromosome loss and aneuploidy (Kikyo and Wolffe, 2000).  To facilitate proper 
nuclear remodeling by MPF, the donor nuclei should be in G1 phase or G0 phase, in 
which the cells remain metabolically active but have exited the cell cycle.  Donor nuclei 
in G1 or G0 phase transferred to recipient oocytes containing high levels of MPF will 
condense normally and maintain correct ploidy of subsequent embryos at the end of the 
first cycle (Campbell et al., 1993; Macháty et al., 2002).  The usefulness of quiescent 
cells has been attributed to their reduced transcriptional activity and chromatin 
modifications that are associated with cells in G0, which may enhance their epigenetic 
plasticity (Armstrong et al., 2006). 
 A number of critical processes must occur and a temporal pattern of events will 
have to be obeyed in order to achieve reprogramming of the somatic cell nucleus by 
SCNT.  These processes include transcriptional silencing of the donor nucleus, erasure 
of differentiated cellular memory, appropriate activation of the reconstructed “one-cell 
embryo”, and appropriate embryonic gene expression at all later stages of development 
(Santos and Dean, 2004).  This cascade of reprogramming of events is initiated by the 
exchange of proteins that occurs when a somatic cell donor nucleus is transplanted into 
an enucleated oocyte.  The first indication of nuclear reprogramming is the breakdown 
of the somatic cell nuclear envelope.  As discussed above, nuclear envelope breakdown 
is associated with high MPF levels.  Soon thereafter, the somatic cell chromosomes 
begin to condense.  All of the factors necessary for reprogramming the somatic cell 
nuclei back to a totipotent state are present in the MII oocyte cytoplasm.    Researchers 
have been exploring these reprogramming factors since Wilmut et al. (1997) first 
reported the successful production of a cloned sheep, and although more than a decade 
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has passed, they remain largely unknown.  Some proteins have been identified, 
including nucleoplasmin and N1/N2.  Both of these molecular chaperones can mediate 
the transfer of core histones to DNA and the assembly of nucleosomes.  Nucleoplasmin 
plays a role in the exchange of the somatic linker histone variants (H1, H1˚) for oocyte-
specific histone variant B4 and the chromatin structural protein HMG1 (Dimitrov and 
Wolffe, 1996).   
 Since the birth of Dolly, viable NT-derived offspring have been produced in many 
species ranging from domesticated animals such as dogs and goats, to wild animals 
such as African wildcats and wolves (Thuan et al., 2010).  Nevertheless, the overall 
efficiency of SCNT is between 0-3% (number of live offspring as a percentage of the 
number of nuclear transfer embryos) (Paterson et al., 2003).  The majority of cloned 
embryos die in utero, and those embryos that do develop to term often exhibit a variety 
of developmental abnormalities.  Placental abnormalities are a common feature among 
NT embryos and account for the high incidence pregnancy loss associated with NT 
embryos.  It is thought that defects in placental function are also responsible for many of 
the developmental abnormalities in cloned fetuses, including Large Offspring Syndrome 
(Yang et al., 2007).    
While a great deal of the attention “Dolly” garnered stemmed from intense public 
debate over ethical concerns regarding cloning, many in the agricultural, scientific and 
medical community were excited over the potential applications of SCNT. SCNT may be 
used to produce multiple copies of a genetically superior farm animal with proven 
performance.  Additionally, SCNT may be used to preserve endangered species.  Given 
that somatic cells are easily obtained from adult animals, cultured in the laboratory and 
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then genetically modified, cloning procedures are ideal for introducing specific genetic 
modifications in farm animals.  Transgenic animal production provides numerous 
opportunities not only for agriculture, but for biomedicine as well, as these animals can 
be used for the production of pharmaceutical proteins or xenotransplantation (Whyte 
and Prather, 2011).   In recent years, however, the potential capabilities of SCNT have 
been overshadowed by ethical concerns as well as the inefficient nature of the 
procedure, leading researchers to explore alternative reprogramming methods for the 
generation of ESC-like cells.   
Fusion with ESC 
Cell fusion studies date back to the 1960’s.  These pioneering experiments 
provided novel evidence that gene expression is regulated not only by cis-acting DNA 
elements but also by trans-acting repressors (Harris et al., 1969; Miller and Ruddle, 
1976; Weiss et al., 1977).  Approximately a decade later, cell fusion studies offered the 
first definitive evidence that the differentiated state of mammalian somatic cells is not 
fixed and irreversible but, instead, is dictated by the balance of regulators and requires 
continuous regulation (Blau et al., 1983; Blau et al., 1985; Blau and Baltimore, 1991).  
Such studies could not be taken further until recent molecular technologies were 
developed, at which point cell fusion experiments showed that the pluripotent state can 
dominate over the differentiated state under certain conditions, resulting in the activation 
of previously silenced genes (Yamanaka and Blau, 2010).  Tada and colleagues (1997) 
reported the first successful reprogramming of somatic cells in proliferative hybrids after 
they fused female EGC with thymocytes from an adult male.  They continued their cell 
fusion experiments, and in 2001 reported that thymocytes were reprogrammed to a 
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pluripotent state after being fused with mouse ESC (mESC).  48 hours after fusion with 
mESC, Oct-4 was reactivated in hybrid cells, indicating pluripotency had been 
reestablished.    This was also testified by the hybrids’ contribution to all three germ 
layers as well as the epigenetic status as assessed by DNA methylation patterns of 
imprinted and non-imprinted genes (Tada et al., 2001).  Rathjen and colleagues (2002) 
produced similar results when they fused mouse ESC-derived neuroectoderm with 
undifferentiated mouse ESC, resulting in hybrid cells that expressed pluripotency-
associated genes at levels comparable to those in ESC.    To test if human ESC were 
capable of nuclear reprogramming like their murine counterpart, Cowan et al (2005) 
fused human ESC with human fibroblast cells.  Following fusion, hybrid cells containing 
both ESC and fibroblast cell chromosomes in a single nucleus were formed; however, 
the hybrid cells exhibited characteristics consistent with the ESC, indicating that the 
phenotype of human ESC is dominant and that they are also capable of  reprogramming 
human somatic cells (Cowan et al., 2005).  Furthermore, DNA analysis showed that the 
promoter region of Oct-4 in the hybrid cells was demethylated and indistinguishable 
from that found in human ESC, proving that the epigenetic information controlling the 
transcription of pluripotency genes was reprogrammed (Cowan et al., 2005).  
 Unlike the ooplasm of an enucleated oocyte in SCNT, nuclear reprogramming of 
a somatic cell to a less differentiated state through cell fusion is governed by ESC 
nuclei, which reactivates pluripotency-associated genes and silences the gene 
expression of the somatic cell.  When the nucleus and the cytoplasm of mESC were 
fused with neurosphere cells, only karyoplasts, not cytoplast, could reactivate Oct-4 in 
the somatic genome (Do and Schöler, 2004).  This is consistent with cloning 
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experiments in amphibians and mice, which indicate that successful reprogramming 
depends on direct injection of nuclei into the MII oocyte, where nuclear factors are 
available in the cytoplasm (Hochedlinger and Jaenisch, 2006).   
Cell fusion is an attractive approach to studying pluripotency and the regulatory 
mechanisms involved in nuclear reprogramming.  Although it is well established that 
somatic cells can be reprogrammed to a pluripotent state through fusion with various 
pluripotent cell types, cell fusion for the generation of pluripotent cells for clinical or 
therapeutic application is not best.   Hybrid cells contain an abnormal ploidy as well as 
nonautologous genes from the pluripotent parent, which could result in immune 
rejection (Pralong et al., 2006).  Removal of the pluripotent genome must be achieved 
before the hybrid cells can be used clinically.   
Exposure to ESC Extracts 
Cell fusion experiments involving the fusion of pluripotent cell types with various 
somatic cell types provided critical insight of the molecular regulators of nuclear 
reprogramming.  The work of Tada and colleagues (1997, 2001) as well as Cowen and 
colleagues (2005) showed that pluripotent cells can trigger epigenetic reprogramming to 
a less differentiated state in a variety of somatic cell types after cellular fusion, proving 
that pluripotent cell types harbor dominant reprogramming activities.  It was experiments 
like these that provided the inspiration for the development of a cell-free means to 
reprogramming the nuclei of somatic cells to a pluripotent state. One such way of doing  
this is through exposure to ESC extracts.  Ha°kelien et al (2002) had previously 
demonstrated the reprogramming abilities of cellular extracts using human 293T 
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fibroblast cells and human T cells.  Ha°kelien et al (2002) derived nuclear and 
cytoplasmic extracts from human peripheral blood T cells by lysing the cells using a 
sonicator.  For the 293T cells to take up the T cell extracts, their cellular membrane was 
permeabilized using Streptolysin O (SLO), which binds to cholesterol in the cell 
membrane and forms holes in the plasma membrane of the cell.  The T cell extracts and 
the permeabilized 293T cells were incubated together for approximately 50 min and 
then the plasma membrane was resealed using a CaCl2-containing cocktail (Ha°kelien 
et al., 2002).  Plasma membrane resealing following SLO exposure is dependent upon 
Ca+2, as the  Ca+2 influx triggers a rapid repair process to the permeabilized plasma 
membrane (Walev et al., 2001).   
Using the same method of extract derivation and membrane permeabilization as 
described by Ha°kelien et al (2002), Taranger and colleagues (2005) demonstrated that 
extracts from both undifferentiated ECC and ESC can induce somatic cells to 
dedifferentiate and, in turn, acquire pluripotent characteristics.  293T cells exposed to 
human teratocarcinoma NCCIT cell extracts and mESC extracts formed defined 
colonies that were maintained for an extended period of time in culture.  Gene 
expression profiling revealed a dynamic up-regulation of genes associated with 
undifferentiated cell types, parallel with down-regulation of 293T cell genes and other 
genes associated with differentiated cell types.  Pluripotency-associated genes Oct-4, 
Nanog, and Sox-2 were among the genes up-regulated in 293T cells exposed to 
extracts of undifferentiated cell types.  Bisulfite sequencing revealed that the Oct-4 
promoter was demethylated in extract-treated 293T cells, suggesting that NCCIT and 
mESC extracts are capable of eliciting Oct-4 demethylation in somatic cells. 
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Additionally, extract-treated 293T cells demonstrated multilineage differentiation 
capabilities by giving rise to cell types of the three germ layers (Taranger et al., 2005).   
 In an effort to better understand the molecular processes underlying nuclear 
reprogramming, researchers built upon this study and were able to provide evidence of 
reprogramming of DNA methylation and histone modifications on the Nanog promoter 
and throughout the Oct-4 regulatory region in human epithelial cells (Freberg et al., 
2007).  In order to identify those cells that had been stably reprogrammed to express 
pluripotency-associated genes, the treated cells in all of the aforementioned studies had 
to be grown in culture for several weeks, which makes it difficult to ascertain 
reprogramming efficacy as well as complicating further biochemical analysis procedures 
(Bru et al., 2008).  In 2008, however, Bru et al. reported the detection of key 
pluripotency-associated genes in ESC-extract treated cells within a few hours of 
exposure, proving the first stages of reprogramming do not require a long incubation 
period.   Interestingly, the expression of these genes increased in the 48 hours following 
exposure to extracts, indicating that long-term reprogramming of gene expression had 
been induced (Bru et al., 2008).  While further studies to validate extract-based nuclear 
reprogramming are needed, it has proven to be an effective means to nuclear 
reprogramming, which may be a more appealing option of generating iPSC than by 
either SCNT or cell fusion.  
Nuclear reprogramming techniques are believed to be immensely beneficial in 
the study and treatment of disease as the direct reprogramming of somatic cells 
provides an opportunity to generate patient- or disease-specific pluripotent stem cells 
(Nakagawa et al., 2008). While all four experimental techniques have demonstrated the 
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ability to successfully reprogram gene expression and promote pluripotency in 
terminally differentiated cells (Thomson et al., 1998; Cowan et al., 2005; Takahashi and 
Yamanaka, 2006; Bru et al., 2008), not all of the methods are suitable for generating 
iPSC for clinical use.  Aside from the obvious ethical issues regarding nuclear 
reprogramming by SCNT and fusion with ESC, major technical obstacles impede their 
clinical applications.  The inefficient nature of SCNT, coupled with the fact that it is a 
technically challenging procedure, make it unlikely that SCNT could be performed on a 
large scale to derive pluripotent cell lines routinely for every patient (Amabile and 
Meissner, 2009).  Although nuclear reprogramming by fusion with ESC circumvents 
these hindrances, abnormal ploidy and the presence of nonautologous genes from the 
pluripotent parent cells prevent the therapeutic use of pluripotent hybrid cells (Pralong et 
al., 2006). For this approach to be viable, a practical means of removing the nucleus of 
the ESC from the hybrid cell must be developed in order to generate diploid customized 
cells for transplantation therapy.  It will be difficult, if not impossible, to selectively 
eliminate the entire set of ESC chromosomes from the hybrid cells if future research 
determines DNA replication is required for reprogramming (Hochedlinger and Jaenisch, 
2006).   
 Extract-based nuclear reprogramming of differentiated somatic cells is an 
attractive means of generating large quantities of pluripotent cells.  Two advantages of 
extract-mediated nuclear reprogramming are the absence of introduction of ESC 
chromosomes into the cell to be reprogrammed, and the possibility of identifying 
reprogramming factors and mechanisms of reprogramming (Collas, 2007).  Extract-
derived factors are presumably not permanently active in target cells but turn over at 
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kinetics corresponding to their half-lives.  By circumventing the use of whole cells, the 
difficulties associated with removal of extra chromosomes are eliminated (Dittmar et al., 
2009).  Furthermore, the use of permeabilized cells allows the reprogramming factors to 
access the interior directly, which may not only be more effective but has the advantage 
of being useful without having a great deal of prior knowledge of regulatory mechanisms 
controlling cell function.  From a commercial standpoint, extract-based reprogramming 
is far more practical than SCNT.  Cells are the source of reprogramming material, 
which, unlike oocytes, can be grown in large numbers, and, if necessary, can be 
transformed to produce a consistent supply of reprogramming material.  Importantly, in 
vitro reprogramming may be applied to many cell types and thus has potential to treat 
many diseases (Collas, 2007).    
Defined Factors 
One of the most significant breakthroughs in stem cell research to occur in recent 
years is the production of iPSC by defined factors.  Indeed, it is arguably the most 
celebrated scientific advancement since the birth of “Dolly”.  Like the previously 
mentioned methods of generating iPSC, the ectopic expression of defined transcription 
factors can also generate genetically-tailored stem cells for therapeutic use by 
reprogramming the nucleus of a differentiated cell to function like that of an ESC.  In 
contrast to the production of iPSC by SCNT, fusion with ESC or exposure to ESC 
extracts, the defined factors methodology is far less controversial because it does not 
make use of ESC or oocytes.  Instead, this technique relies upon the actions of four 
transcription factors to elicit pluripotent cells from otherwise developmentally-restricted 
cells.  Considering the transcription factors known to function in the maintenance of 
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pluripotency in ESC as well as those specifically expressed in ESC, Takahashi and 
Yamanaka (2006) selected 24 genes as contenders for factors capable of inducing 
pluripotency in somatic cells.  To determine which genes are critical for reprogramming 
a somatic cell to an ESC-like state, Takahashi and Yamanaka (2006) developed an 
assay system in which a gene’s ability to induce pluripotency was determined by its 
ability to trigger the formation of G418-resistant colonies following its induction to mouse 
embryonic fibroblast cultures by retroviral transduction.   Of these 24 genes, Oct-4, Sox-
2, c-Myc and Klf-4 were identified as the essential factors for generating iPSC directly 
from fibroblast culture (Takahashi and Yamanaka, 2006).  The resultant iPSC exhibited 
morphological features and proliferative properties consistent with ESC, and also 
expressed ESC marker genes.  Furthermore, subcutaneous injection of the iPSC in 
nude mice elicited the formation of teratomas that contained tissues from all three germ 
layers, indicative of the pluripotent state of the iPSC (Takahashi and Yamanaka, 2006).  
The crucial roles Oct-4 and Sox-2 play in maintaining ESC identity are well established; 
therefore, it was not surprising to discover they also serve in the direct production iPSC 
in culture.  However, it was surprising to find that Nanog, whose expression is essential 
to the pluripotent-state of ESC, was dispensable to this process, whereas c-Myc and 
Klf-4 were imperative (Takahashi and Yamanaka, 2006).  c-Myc and Klf-4 are proposed 
to indirectly enhance Oct-4, Sox-2 and Nanog function, respectively, in the iPSC.  It is 
believed that c-Myc may induce global histone acetylation in the mammalian genome 
(Fernandez et al., 2003), which, in turn, potentiates Oct-4 and Sox-2 target binding.  Klf-
4, on the other hand, may contribute to Nanog activation by repressing p53, which is 
known to suppress Nanog expression in ESC during differentiation (Lin et al., 2005).  
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Indeed, the exact mechanisms these factors employ to induce pluripotency in somatic 
cells is undetermined, however, their ability to do so is universal. Although human ESC 
differ from murine ESC in many aspects, Takahashi et al. (2007) reported the 
generation of iPSC from adult human fibroblast cultures using the same defined factors 
less than a year after their initial study.  The functional uniformity of Oct-4, Sox-2, c-Myc 
and Klf-4 across species suggests that these four factors are fundamentals of a 
common pluripotency-governing system.  Furthermore, the similarities in morphology, 
proliferation, surface antigens, gene expression, epigenetic status of pluripotent cell-
specific genes, telomerase activity, and pluripotent differentiation ability noted between 
human iPSC and true human ESC (Nakagawa et al., 2008) are similar to those 
observations between murine iPSC and murine ESC (Takahashi and Yamanaka, 2006).   
Epigenetic Reprogramming 
 In all of the aforementioned reprogramming strategies, differentiated somatic 
cells are reverted to an ESC-like state as a result of changes in the epigenome.  
Although epigenetic modifications are heritable, all four reprogramming methodologies 
have demonstrated that these modifications can be experimentally reversed.  
Epigenetic changes are heritable modifications to DNA or chromatin that allow 
differentiated cells to perpetuate the molecular memory needed to retain their identity 
(Tada et al., 1997; Jones and Takai, 2001).  The principle function of epigenetic 
modifications is to regulate the repression of genes not required in specific cell types at 
specific stages of development without changing DNA sequence (Wolffe and Matzke, 
1999).   
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Successful reprogramming of somatic cells towards pluripotency requires the 
epigenetic marks characteristic of the differentiated cell type first be erased in order to 
inactivate the somatic cell program and activate the embryonic program.   Recent 
studies reporting the activation of the embryonic marker SSEA 1 following the 
downregulation of somatic markers, such as Thy 1 and collagens, provide evidence in 
support of the notion that silencing the somatic cell program is an important initial step 
in re-establishing pluripotency (Brambrink et al., 2008; Stadtfeld et al., 2008).  The 
activation of SSEA 1 in reprogrammed fibroblast cells is an especially important 
intermediate stage of transcription factor-induced reprogramming because it promotes 
the gradual reactivation of other markers associated with pluripotency, including Oct-4, 
Nanog, Sox-2, telomerase and the silent X chromosome in female fibroblasts 
(Brambrink et al., 2008; Stadtfeld et al., 2008).   
The expression of Oct-4, Nanog, Sox-2 and other pluripotency-associated genes 
is silenced through the differentiation-induced actions of DNA methylation, histone 
deacetylation and histone methylation.  These repressive mechanisms that function to 
silence the embryonic program must be overcome during reprogramming (Hochedlinger 
and Plath, 2009).  Regardless of the methodology employed, nuclear reprogramming is 
associated with a global reversal of DNA methylation.  Both active and passive 
mechanisms of DNA demethylation have been proposed to occur in reprogramming, but 
the precise nature of the mechanisms underlying nuclear reprogramming remains 
largely unknown.  It is possible that reprogramming by defined factors facilitates the 
direct binding of these factors to promoter or enhancer regions of target sites, which 
interfere with the methylation of newly synthesized DNA during DNA replication.  
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Similarly, passive demethylation could also occur as a result of stochastic impairments 
to specific factors known to contribute to the stable inheritance of methylation patterns, 
thus inhibiting Dnmt-1 function indirectly (Hochedlinger and Plath, 2009).   
Inefficient reprogramming in SCNT embryos has been linked to flaws in the 
demethylation process.  This may in part be due to the fact that the somatic nuclei 
contain the somatic form of Dnmt-1, which, unlike the oocyte form, is capable of 
maintaining methylation levels (Reik et al., 2001).    Alternatively, DNA methylation 
could be actively removed by the recruitment of a demethylating enzyme, although the 
presence of demethylation enzymes in mammalians is still under debate (Hochedlinger 
and Plath, 2009).   
Small Molecules 
The notion that the aforementioned repressive mechanisms that function to 
silence the embryonic program actions must be overcome in order for successful 
nuclear reprogramming to occur has prompted the use of various chemical inhibitors 
involved in DNA methylation, histone deacetylation and histone methylation.  Such 
chemical inhibitors aid in overcoming the “roadblocks” encountered during the 
reprogramming process by inducing the necessary epigenetic modifications needed to 
silence the somatic cell genome and completely reactivate the ESC genome. Several 
small molecules, affecting specific signaling pathways and/or chromatin modifications, 
have been shown to improve both the kinetics and efficiency of reprogramming 
(summarized in Table 2.1)(Zhang et al., 2012).  In addition, pre-treatment of cells with  
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Table 2.1. Known compounds that modulate stem cell fate and reprogramming 
Compound 
name 
Identity Function References 
Epigenetic-related compounds 
Valproic acid 
(VPA) 
HDAC inhibitor 
Promotes MEF reprogramming 
efficiency, and enables Oct4- and 
Sox2-mediated reprogramming of 
human fibroblasts; 
(Huangfu et al., 2008a; 
Huangfu et al., 2008b) 
VPA HDAC inhibitor 
facilitates proteins mediated 
reprogramming of MEFs 
(Zhou et al., 2009) 
Suberoylanilide 
hydroxamc acid 
(SAHA) 
HDAC inhibitor 
Promotes MEF reprogramming 
efficiency 
(Huangfu et al., 2008a) 
Trichostatin A 
(TSA) 
HDAC inhibitor 
Promotes MEF reprogramming 
efficiency 
(Huangfu et al., 2008a) 
Sodium butyrate 
(NaB) 
HDAC inhibitor 
Enhances reprogramming efficiency 
of human adult or fetal fibroblasts; 
(Mali et al., 2010) 
NaB HDAC inhibitor 
facilitates Oct4-only mediated 
reprogramming when combined with 
A-83-01/PD0325901/PS48 
(Zhu et al., 2010) 
BIX-01294 
G9a HMT 
inhibitor 
Enables NPC reprogramming 
mediated by Oct4 and Klf4, or 
substitutes for Oct4 in NPC 
reprogramming; 
(Shi et al., 2008b) 
BIX-01294 
G9a HMT 
inhibitor 
promotes MEF reprogramming 
mediated by Oct4 and Klf4 
(Shi et al., 2008a) 
RG108 DNMT inhibitor 
Promotes MEF reprogramming 
mediated by Oct4 when combined 
with BIX-01294 
(Shi et al., 2008a) 
Parnate LSD1 inhibitor 
Enables reprogramming of human 
keratinocytes mediated by Oct4 and 
Klf4; 
(Li et al., 2009b) 
Parnate LSD1 inhibitor 
facilitates the conversion of mEpiSCs 
to naïve pluripotent state 
(Zhou et al., 2010) 
Table Cont’d 
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Compound 
name 
Identity Function References 
PD0325901 MEK inhibitor 
Blocks differentiation pathway of 
ESCs and supports self-renewal; 
(Ying et al., 2008; 
Tsutsui et al. 2011) 
PD0325901 MEK inhibitor 
supports ESC derivation from 
refractory strains or species; 
(Nichols et al., 
2009;Buehr et al., 
2008; Li et al., 2008) 
PD0325901 MEK inhibitor 
facilitates conversion of mEpiSCs and 
hESCs to naïve pluripotent state; 
(Hanna et al., 2010; 
Zhou et al., 2010) 
PD0325901 MEK inhibitor 
facilitates generation and 
maintenance of mESC-like rat or 
human iPSCs; 
(Li et al., 2009a) 
PD0325901 MEK inhibitor 
facilitates rapid and efficient 
generation of fully reprogrammed 
hiPSCs; 
(Lin et al., 2009) 
PD0325901 MEK inhibitor 
enables Oct4-mediated 
reprogramming when combined with 
A-83-01/NaB/PS48 
(Zhu et al., 2010) 
CHIR99021 GSK3 inhibitor 
Supports ESCs self-renewal; 
facilitates ESCs derivation from 
refractory stains or species 
(Ying et al., 2008; 
Tsutsui et al. 2011) 
CHIR99021 GSK3 inhibitor 
captures and maintains lineage-
specific stem cells, like pNSCs; 
facilitates the conversion of mEpiSCs 
and hESCs to naïve pluripotent state; 
(Nichols et al., 2009; 
Buehr et al., 2008; Li et 
al., 2008) 
CHIR99021 GSK3 inhibitor 
enables Oct4- and Klf4-mediated 
reprogramming of MEFs or human 
primary keratinocytes with Parnate; 
(Li et al., 2009a; Hanna 
et al., 2010; Zhou et al., 
2010; Li et al., 2009b) 
CHIR99021 GSK3 inhibitor 
facilitates generation and 
maintenance of mESC-like rat or 
human iPSCs; 
(Li et al., 2009a) 
CHIR99021 GSK3 inhibitor 
facilitates the neural conversion of 
human fibroblasts mediated by Ascl1 
and Ngn2 
(Ladewig et al., 2012) 
Table Cont’d 
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Compound 
name 
Identity Function References 
6-
bromoindirubin-
3′-oxime (BIO) 
GSK3 inhibitor 
Promotes self-renewal of ESCs and 
Isl+ cardiovascular progenitors 
(Sato et al., 2004; 
Qyang et al., 2007) 
Kenpaullone 
GSK3 and CDK 
inhibitor 
Replaces Klf4 in MEF reprogramming (Lyssiotis et al., 2009) 
PD173074 
FGF receptor 
inhibitor 
Supports mESC self-renewal; (Buehr et al., 2008) 
PD173074 
FGF receptor 
inhibitor 
facilitates the conversion of mEpiSCs 
to naïve pluripotent state 
(Zhou et al., 2010) 
SU5402 
FGF receptor 
inhibitor 
Supports mESC self-renewal (Buehr et al., 2008) 
A-83-01 
ALK4, ALK5, 
ALK7 inhibitor 
Facilitates the conversion of mEpiSCs 
to naïve pluripotent state; 
(Zhou et al., 2010) 
A-83-01 
ALK4, ALK5, 
ALK7 inhibitor 
enables generation and long-term 
maintenance of mESC-like human 
iPSCs; 
(Li et al., 2009a) 
A-83-01 
ALK4, ALK5, 
ALK7 inhibitor 
enables Oct4-mediated 
reprogramming when combined with 
PD0325901/NaB/PS48 
(Zhu et al., 2010) 
SB431542 
ALK4, ALK5, 
ALK7 inhibitor 
Captures and maintains pNSCs when 
combined with CHIR99021; 
(Li et al., 2011) 
SB431542 
ALK4, ALK5, 
ALK7 inhibitor 
facilitates rapid and efficient 
generation of fully reprogrammed 
human iPSCs; 
(Lin et al., 2009) 
SB431542 
ALK4, ALK5, 
ALK7 inhibitor 
Facilitates the neural conversion of 
human fibroblasts mediated by Ascl1 
and Ngn2 
(Ladewig et al., 2012) 
E-616452 
ALK4, ALK5 and 
ALK7 inhibitor 
Replaces Sox2 in MEF 
reprogramming. 
(Ichida et al., 2009; 
Maherali and 
Hochedlinger, 2009) 
Compound E 
γ-secretase 
inhibitor 
Accelerates the generation of pNSCs (Li et al., 2011) 
Table Cont’d 
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Compound 
name 
Identity Function References 
JAK Inhibitor I JAK inhibitor 
Inhibits the generation of iPSCs in 
iPSC-TF-based transdifferentiaion 
(Efe et al., 2011; Kim et 
al., 2011a) 
Pluripotin (SC1) 
RasGAP and 
ERK inhibitor 
Maintains mESC self-renewal (Chen et al., 2006) 
Y-27632 ROCK inhibitor 
Improves survival of hESCs upon 
dissociation 
(Chen et al., 2010; 
Ohgushi et al., 2010; 
Xu et al., 2010) 
Thiazovivin 
(Tzv) 
ROCK inhibitor 
Improves survival of hESCs upon 
dissociation; 
(Xu et al., 2010) 
Thiazovivin 
(Tzv) 
ROCK inhibitor 
facilitates rapid and efficient 
generation of fully reprogrammed 
hiPSCs 
(Lin et al., 2009) 
StemRegenin1 AhR antagonist 
Enables ex vivo expansion of CD34+ 
HSCs ex vivo 
(Boitano et al., 2010) 
PS48 PDK1 activator 
Enables OCT4-mediated 
reprogramming with A-83-01, NaB 
and PD0325901 
(Zhu et al., 2010) 
BayK8644 
L-type Ca2+ 
channel agonist 
Promotes MEF reprogramming 
mediated by Oct4 and Klf4 when 
combined with BIX-01294 
(Shi et al., 2008a) 
Forskolin PKA agonist 
Induces Klf4 and Klf2 expression to 
facilitate hESCs conversion into a 
naïve pluripotent state 
(Hanna et al., 2010) 
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chemical inhibitors can remodel the epigenetic landscape of the somatic cell type to be 
more like that of ESC by removing  the repressive epigenetic marks and relaxing 
chromatin structure to allow the reprogramming factors easier access to target genes.   
DNA Methyltransferase Inhibitors 
Methylated CpG sites in gene promoter regions are easily recognized by specific 
methyl CpG binding proteins, which act as adapters between methylated DNA and 
chromatin modifying factors.  These proteins can recruit co-repressors, such as histone 
deacetylases (HDAC), methyltransferases, and chromatin remodeling factors, creating a 
protein complex that regulates gene expression.  If the promoter region is methylated, 
the corresponding gene’s expression is suppressed due to its’ inability to recognize 
transcription factors (Gnyszka et al., 2013).   
5-azacytidine (AZA) is the most commonly used DNA methyltransferase (DNMT) 
inhibitors.  Once incorporated into the genome, 5-AZA disrupts the interaction between 
DNA and DNMTs through nitrogen, instead of carbon, in the 5-position of the modified 
pyrimidine (Gnyszka et al., 2013).  The enzyme remains covalently bound to DNA and 
its DNMT, thus blocking its function.  Additionally, the covalent protein adduction also 
compromises the functionality of DNA and triggers DNA damage signaling, resulting in 
the degradation of trapped DNMTs.  As a result, further methylation of cytosine residues 
is inhibited, causing the passive loss of cytosine methylation in daughter cells 
(Stresemann and Lyko, 2008).  
As previously mentioned, the vast majority of cells subjected to direct 
reprogramming conditions are trapped in an intermediate state that is characterized by 
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the downregulation of somatic genes, maintenance of viral transgene expression, 
incomplete reactivation of pluripotent genes, inability to form chimeras, and persistent 
DNA hypermethylation.  Mikkelsen et al., (2008) demonstrated that these partially 
reprogrammed cells can be coaxed to undergo complete reprogramming by treatment 
with 5-AZA.  Furthermore, treatment with 5-AZA was also shown to improve the number 
of ESC-like colonies by 4-fold (Mikkelsen et al., 2008).   
Histone Deacetylase Inhibitors 
 Acetylation plays an important role in nucleosome assembly and chromatin 
folding.  Acetylation favors an open chromatin structure by interfering with the 
interactions between nucleosomes and releasing the histone tails from the linker DNA.  
Chromatin regions that are marked by lysine acetylation catalyzed by Histone Acetyl-
transferase (HATs) are generally actively transcribed, whereas regions that are bound 
by Histone Deacetylases (HDACs) bear deacetylated lysines and are inactive 
(Shahbazian and Grunstein, 2007; Kretsovali et al., 2012).   
 HDAC inhibitors (HDACis) are small molecules that inhibit the activities of 
HDACs, thus playing a major role in epigenetic regulation.  Consequently, HDACis have 
been widely utilized in nuclear reprogramming.  Trichostatin A (TSA) and valproic acid 
(VPA) are among the most commonly used HDACis, and their role as an effective 
facilitator of nuclear reprogramming has been well documented.  Huangfu and 
colleagues (2008a) demonstrated the ability to generate iPSC in the absence of c-myc 
by substituting it for VPA.  Using the pluripotency factors Oct-4, Sox-2, and Klf-4 and 
VPA, they were not only able to reprogram primary human fibroblast cells into iPSC, but 
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they were also able to increase the number of iPSC colonies by 50-fold. In another 
study by Huangfu and colleagues (2008b), it was shown that the combination of Oct-4, 
Sox-2, and VPA was sufficient to reprogram somatic cells at an efficiency similar to that 
of three factor reprogramming.  It should be noted that other combinations of two factors 
did not yield any iPSC, even in the presence of VPA, suggesting that Oct-4 and Sox-2 
are indispensable in reprogramming human fibroblasts in the context of VPA treatment.  
That being said, mouse embryonic fibroblasts (MEFs) treated only with VPA exhibited 
an upregulation of ESC-specific genes, while MEF-specific genes were downregulated.  
This suggests that VPA may support a predisposition towards an ESC-like state.  
Furthermore, the genome-wide acetylation induced by VPA and other HDACis could 
allow MEFs to adopt a relaxed chromatin structure that facilitates the binding of 
ectopically expressed transcription factors or downstream secondary factors (Feng et 
al., 2009).   
Other Small Molecules 
 Histone lysine methylation plays a key role in the organization of chromatin 
domains and the regulation of gene expression; however, aberrant expression of 
histone lysine methyltransferasees (HMTases) like G9a has been linked to tumor 
development.  G9a is a H3K9 methyltransferase, which is localized exclusively in 
euchromatic regions.  It functions to repress gene activity by inducing local H3K9me2 
and H3k9me3 at target promoters (Kubicek et al., 2007).  In addition to inducing di- and 
tri-methylation of H3K9, G9a methylates K373 of p53, a tumor suppressor.  
Overexpression of G9a results in the inactivation of p53, which is implicated in over 
50% of cancers (Huang et al., 2010).   Studies have shown that knockout of G9a inhibits 
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cancer growth (McGarvey et al., 2006; Kondo et al., 2008), leading researchers to 
explore G9a inhibition as a potential approach for cancer treatment.   
 BIX-01294 has been identified as a small-molecule inhibitor of G9a.  BIX-01294 
does not compete with the cofactor S-adenosyl-methionine, and is highly selective for 
G9a.  Importantly, BIX-01294 is biologically active in reducing H3K9me2 levels at 
several G9a target genes, thereby allowing for the transient reversal of this repressive 
mark in vitro (Kubicek et al., 2007).  Among the many genes G9a HTMase regulates is 
the pluripotency gene, Oct-4.  The quest to generate iPSC efficiently and without viral 
genome integration lead Shi et al (2008a) in search of a chemical cocktail that would 
allow reprogramming of somatic cells in chemically defined conditions.  In this study, 
neural progenitor cells (NPC), which endogenously express Sox-2 (Blelloch et al., 
2006), were transduced with only Oct-4 and Klf-4 and were successfully reprogrammed 
to iPSC.  They found reprogramming to be greatly enhanced by the presence of BIX-
01294.  Furthermore, BIX-01294 was shown to enable reprogramming of NPC 
transduced with c-Myc, Klf-4, and Sox-2, in the absence of Oct-4 ectopic expression.  In 
this particular system, BIX-01294 seemed to compensate for the lack of Oct-4 
overexpression (Shi et al., 2008a).  In a follow-up study by Shi and colleagues, they 
aimed to assess if a similar strategy could be used to find small molecules that can 
replace viral transduction to obtain iPSC from a general cell line, mouse embryonic 
fibroblasts (MEF), in which none of the transcription factors deemed essential for 
reprogramming, Oct-4, Sox-2, and Klf-4, are expressed.  They found that a combination 
of BIX-01294 and Bayk8644, a L-channel calcium agonist, was effective at enabling the 
generation of iPSC from MEF transduced with only Oct-4 and Klf-4 (Shi et al., 2008b).   
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Their interest in Bayk8644 stems from the fact that it exerts its effects upstream in cell 
signaling pathways and does not directly cause epigenetic modifications; therefore, it 
can likely be exploited to induce reprogramming in a more specific manner than 
molecules acting directly at the epigenetic level causing DNA or histone modification 
(Shi et al., 2008b).  Activation of L-type calcium channels by different agonists, including 
Bayk8644, has been shown to induce intracellular signaling through CREB activation, 
sacoplasmic reticulum calcium release, and change in cAMP activity.  Furthermore, it 
has been suggested that calcium may play a role in the control of mESC proliferation 
(Heo et al., 2006).  However, Shi et al (2008b) observed no change in proliferation when 
mESC were treated with Bayk8644 alone or in combination with BIX-01294.  Treatment 
of MEF with Bayk8644 alone or in combination with BIX-01294 did not induce Sox-2 
expression either, making it rather interesting that Bayk8644 improves reprogramming 
efficiency.  While further work is needed to dissect the exact mechanism by which 
Bayk8644 improves the reprogramming process, it is interesting to find that a small 
molecule with activity in signaling pathways that have not been previously linked to 
reprogramming can significantly enhance its efficiency (Shi et al., 2008b).  To date, it is 
the only small molecule of its type to show an effect of reprogramming, as most of the 
other small molecules identified appear to directly modify the epigenetic status of the 
cell: BIX-01294 (Shi et al., 2008a), VPA (Huangfu et al., 2008), and 5-AZA (Mikkelsen et 
al., 2008).  Because Bayk8644 does not reprogram on its own but requires the 
presence of BIX-01294 to exert its effects, this suggests that cells that are already 
undergoing a form of reprogramming, may be more susceptible to its effect, making it 
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possible to reprogram the target cell in a more specific manner, without impacting 
healthy cells systemically, as direct epigenetic modifier might (Shi et al., 2008b).   
 Small molecules are also employed to target specific signaling pathways that 
coincide with the pluripotent state. The role Leukemia Inhibitory Factor (LIF) and Bone 
Morphological Protein (BMP) play in the self-renewal of murine ESC has been well 
established (Niwa et al., 1998); therefore, it was surprising to discover that mESCs 
could sustain their identity in the absence of LIF and BMP.   Chen and colleagues 
(2006) identified a synthetic small molecule known as Pluripotin, which enabled mESC 
to maintain long-term self-renewal under feeder-, serum-, and LIF-free conditions.  
Pluripotin inhibits two endogenous differentiation-inducing proteins, Ras GTPase-
activating protein (RasGAP) and ERK1 (also known as MAPK3), thus allowing 
pluripotency to be sustained without the use of exogenous factors to activate 
pluripotency-associated pathways.  The identification of Pluripotin revealed a 
fundamental strategy for maintaining stem cell self-renewal through the inhibition of 
endogenous differentiation mechanisms, and explained how combining the activation of 
differentiation-inducing pathways with the modulation of other pathways can sustain 
self-renewal by effectively balancing out the differentiation activity of stem cells (Zhang 
et al., 2012).  Similarly, PD0325901, a mitogen activated protein kinase/ERK kinase 
(MEK) inhibitor, and CHIR99021, a glycogen synthase kinase-3 (GSK3) inhibitor, have 
also been shown to facilitate the maintenance of mESC without the need for feeder cells 
or exogenous cytokines (Buehr et al., 2008).  Inhibition of both the MEK and GSK3 
pathways eliminates the need for LIF and BMP in mESCs.  Stimulation of the ERK 
signaling pathway triggers the transition from pluripotency to lineage-commitment 
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(Kunath et al.,2007); therefore, by blocking the ERK signaling pathway, lineage-
commitment is inhibited and the ground state of ESC self-renewal is maintained (Ying et 
al., 2008).  
Increased understanding of signaling pathways and their role in cellular identity 
has greatly advanced iPSC technology.  Although the strategy developed by Takahashi 
and Yamanaka for generating iPSC has enormous therapeutic potential, it is not an 
infallible technique, and, despite substantial progress in recent years, a number of 
challenges remain.  Reprogramming remains a largely inefficient and non-specific 
process, with efficiencies of transduced cells becoming fully reprogrammed iPSCs lower 
than 0.01% (Takahashi et al., 2007; Yu et al., 2007; Hasegawa et al., 2010).  The 
majority of transduced cells become trapped in a pre-iPSC state that is characterized by 
the downregulation of somatic cell marker genes, incomplete reactivation of 
pluripotency genes, maintenance of viral expression, and the inability to form chimeras.  
To achieve complete reprogramming, DNA methylation, histone modification, and 
chromatin structure need to mimic that of the embryonic environment.  The introduction 
of key transcription factors (Oct-4, Sox-2, Klf-4, c-myc) initiate a number of complex 
processes that cooperatively function to reboot the epigenetic state of the somatic cell 
type.  C-myc is believed to loosen the tight chromatin structure characteristic of somatic 
cells, which allows Oct-4 and Sox-2 to co-bind their target genes to launch the 
pluripotent network (Takahashi and Yamanaka, 2006; Wernig et al., 2008).  Among 
these targets are a group of genes that encode for epigenetic factors that participate in 
the maintenance of self-renewal and pluripotency (Loh et al., 2006).  Several studies 
have shown that small molecules can improve reprogramming when combined with 
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conventional reprogramming factors (Huangfu et al., 2008; Mikkelsen et al., 2008; Shi et 
al., 2008b).  The relief of repression on key pluripotency genes such as Oct-4 and 
Nanog may allow an earlier induction of self-renewal and pluripotency (Feng et al., 
2009).  Similarly, Silva and colleagues (2008) demonstrated that partially reprogrammed 
cells can be coaxed out of this state and transition to fully reprogrammed iPSCs by 
treatment with the chemicals PD0325901 and CHIR99021 to inhibit MEK and GSK3, 
respectively.  These chemical inhibitors could potentially induce a global permissive 
epigenetic landscape similar to ESCs by inducing epigenetic changes that promote the 
active transcriptional state and facilitating the erasure of repressive epigenetic features.  
The combination of events may provide exogenous reprogramming factors and 
secondarily-induced transcription factors greater access to downstream target genes.  
Therefore, genetic factors and small molecules may synergiscally modify epigenetic 
features to activate the pluripotent transcriptional network to enhance reprogramming 
(Feng et al., 2009). 
Conclusion 
 In 2006, Shinya Yamanaka made a groundbreaking discovery that would 
ultimately win him the Nobel Prize in Physiology and Medicine just 6 years later.  The 
discovery of iPSC represents the culmination of over 60 years of research, which began 
by asking the simple question: “is cell fate irreversibly fixed as cells become more 
specialized?”  The progression from nuclear transfer in frogs to the generation of 
patient-specific iPSC echoes scientists’ expanding knowledge of the molecular 
machinery that regulate cell fate.  Collectively, these studies prove that a differentiated 
cell can be reverted back to earlier state.  The resetting of the somatic cell nucleus to an 
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embryonic state involves several complex mechanisms, and, despite an increased 
understanding of reprogramming mechanisms, much is still to be learned before its full 
potential can be harnessed.  Nevertheless, research in the field of iPSC is steadfast and 
progress is continuously being made.   
 Studies have revealed that epigenetics play a crucial role in nuclear 
reprogramming.  Resistance to reprogramming is largely attributed to the phenomenon 
of epigenetic memory that cells retain throughout numerous cell divisions.  As cells 
become more differentiated, they acquire epigenetic marks that make their nuclei 
increasingly resistant to reprogramming (Pasque et al., 2011).  However, modulations of 
the epigenetic processes that accompany nuclear reprogramming may facilitate the 
conversion to an epigenetic landscape that is more permissive to reprogramming.  
Various tools have been employed to help cells overcome this reprogramming 
roadblock, including the use of small molecules.  Several chemical compounds that 
control epigenetic enzymes, such as HDAC, HMT, DNMT, and histone demethylase 
(HDM) have been shown to improve reprogramming efficiency, or even replace the 
need to use certain transcription factors (Zhang et al., 2012).  This is especially 
promising for the clinical application of iPSC as there are serious concerns regarding 
the safety of current genetic approaches to nuclear reprogramming, as well as 
traditional culture systems that are used to maintain iPSC.  Small molecules provide an 
attractive approach to addressing these challenges, as they offer a number of 
compelling advantages.  First, the biological effects of small molecules are typically 
rapid, reversible and dose-dependent, allowing precise control over specific outcomes 
by fine-tuning their concentrations and combinations. Second, the structural diversity 
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that can be provided by synthetic chemistry allows the functional optimization of small 
molecules. Third, compared with genetic interventions, the relative ease of the handling 
and administration of small molecules make them more practical for in vitro and in vivo 
applications, and for further therapeutic development (Zhang et al., 2012).   
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CHAPTER III 
EFFECT OF SMALL MOLECULE TREATMENT ON EXPRESSON OF 
PLURIPOTENCY GENES IN BOVINE FETAL FIBROBLAST CELLS 
 
Introduction  
 
Successful reprogramming of somatic cells towards pluripotency requires the 
epigenetic marks characteristic of the differentiated cell type first be erased in order to 
inactivate the somatic cell program and activate the embryonic program.  However, the 
majority of cells subjected to reprogramming conditions become trapped in a partially 
reprogrammed state that is characterized by the downregulation of somatic cell marker 
genes, incomplete reactivation of pluripotency genes, maintenance of viral expression, 
and the inability to form chimeras.  To achieve complete reprogramming, DNA 
methylation, histone modification, and chromatin structure need to mimic that of the 
embryonic environment.  Several small molecules, affecting specific signaling pathways 
and/or chromatin modifications, have been shown to improve both the kinetics and 
efficiency of reprogramming (summarized in Table 2.1).  In pharmacology, a small 
molecule is defined as low molecular weight (<900 Daltons) organic bioactive 
compounds that may help regulate a biological process.  These chemical modifiers aid 
in overcoming the “roadblocks” encountered during the reprogramming process by 
inducing the necessary epigenetic modifications needed to silence the somatic cell 
genome and completely reactivate the ESC genome. Chemical treatment of cells prior 
to reprogramming can remodel the epigenetic landscape of the somatic cell type to be 
more like that of ESC by removing  the repressive epigenetic marks and relaxing 
chromatin structure to allow the reprogramming factors easier access to target genes. 
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In the decade since Takahashi and Yamanaka’s (2006) groundbreaking discovery, 
much effort has been made to better understand the molecular circuitry permitting the 
generation of iPSC in the hopes of improving this reprogramming method.  
Reprogramming by defined factors is an ineffective process, with efficiencies of 
transduced cells becoming fully reprogrammed iPSC lower than 0.01% (Takahashi et 
al., 2007; Yu et al., 2007; Hasegawa et al., 2010).  Furthermore, safety concerns 
regarding the use of exogenous genes and the method of delivering these 
reprogramming factors, as well as technical and logistical challenges have hindered 
clinical applications of iPSC.  Scientists tackled these issues with steadfastness, and a 
number of genetic factors, chemical inhibitors, and signaling molecules have been 
shown to either promote or enhance reprogramming.  Concerns over genome 
modification through exogenous sequences were largely resolved by the introduction of 
new delivery methods, which included the use of episomal plasmids (Yu et al., 2009) or 
excisable expression systems (Soldner et al., 2009), recombinant cell-penetrating 
reprogramming proteins (Kim et al., 2009; Zhou et al., 2010) and reprogramming 
mRNAs (Warren et al., 2010; Yakubov et al., 2010) or microRNAs (Anokye-Danso et al., 
2011; Miyoshi et al., 2011).  Although, genetic methods have been widely used to 
address these issues, a chemical approach offers many advantages.  First, the 
biological effects of small molecules are typically rapid, reversible and dose-dependent, 
allowing precise control over specific outcomes by fine-tuning their concentrations and 
combinations. Genetic approaches, on the other hand, involve permanent genome 
modifications with associated problems of tumorigenicity and other irreversible, 
unintended consequences.  Second, the structural diversity that can be provided by 
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synthetic chemistry allows the functional optimization of small molecules. Whereas 
biological reagents are best suited for targeting extracellular components, small 
molecules are cell-permeable and, therefore, have the potential to target every class of 
macromolecule in the cell.  Third, compared with genetic interventions, the relative ease 
of the handling and administration of small molecules make them more practical for in 
vitro and in vivo applications, and for further therapeutic development (Zhang et al., 
2012).  Because of the advantages, interest in utilizing small molecules in stem cell 
biology and regenerative medicine has significantly heightened.  Table 3.1 summarizes 
the growing number of small molecules that have been identified to maintain self-
renewal potential of stem cells, to induce lineage differentiation, and to facilitate 
reprogramming either by increasing efficiency or by replacing genetic reprogramming 
factors.  Identification of novel small molecules compounds that affect cell fate and 
increased understanding of the nuclear reprogramming process lead Hou et al. (2013) 
to report the first-ever all chemical generation of mouse iPSC from MEF cells. The 
Chemically-induced Pluripotent Stem Cells (CiPSCs) were induced through a very 
complicated procedure with 3-step compound treatment shown in Figure 3.1.  After a 
year of screening 10,000 compounds, they concluded that a cocktail of seven small 
molecules was capable of cell fate reprogramming.  The seven small molecule cocktail, 
known as “VC6TFZ”, is comprised of VPA, CHIR99021, 616452, Tranylcypromine, 
Forskolin (FSK), 2-methyl-5-hydroxytryptamine (2-Me-5HT), and D4476.  Hou et al. 
(2013) identified this potent cocktail by first generating iPSC using the Oct-4 gene in 
combination with CHIR99021, 616452, and Tranylcypromine.   
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Next, they screened different chemical substitutes for Oct-4 using a Oct-4 promoter-
driven GFP expression system.  After screening 10,000 compounds, they concluded 
FSK, 2-Me-5HT, and D4476 could substitute for Oct-4.  VC6TF treatment yielded some 
GFP-positive cell clusters, however neither Oct-4 nor Nanog were detectable in these 
cells, indicating incomplete reprogramming.  They identified one final chemical, 3-
deazaneplanocin (DZNep), to be critical later in the reprogramming process for 
activating endogenous Oct-4.  They designed CiPSC protocol including 3 steps as 
follows: (a) MEF cells were cultured in mESC medium containing VC6FT for 16–20 
days; (b) cells were cultured in the medium with VC6FTZ for 12–20 days; (c) cells were 
cultured in mESC medium containing 2i (PD0325901 and CHIR99021) for 1 week (Hou 
et al., 2013).   
 
 
Figure 3.1 Schematic diagram illustrating direct iPSC reprogramming from 
MEF using only small molecules.  Hou et al.,(2013) reported that CiPSC 
generation from MEF was carried out in three steps of 16-20 days in VC6TF 
treatment, and then 12-20 days in VC6TFZ followed by the application of two 
MEK and GSK3-β inhibitors, known as “2i”, to finalize chemical reprogramming.  
Using a doxycycline (DOX)-inducible GFP-Oct-4 expression screening system, 
ectopic GFP-Oct-4 expression was induced during the first round, followed by 
DOX withdrawal and small molecule treatment.   
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Chemical-only reprogramming is a long, multi-step, sequence-dependent 
process characterized by a unique intermediate state.  The cells at this intermediate 
state have a strong resemblance to embryo-derived extraembryonic endoderm (eXEN) 
cells (Zhou et al., 2010).  eXEN cells are derived from primitive endoderm cells in late 
blastocyst stage embryos and continue to propagate in culture while retaining their 
ability to contribute to extraembryonic cell lineage after injection into blastocysts (Kunath 
et al., 2007). The intermediate cells of chemical reprogramming, designated as 
chemically-induced XEN (CeXEN) cells, express Gata4, Gata6, Sox17, Sox7, and Sall4, 
and also possess the ability to contribute to the extraembryonic cell lineages in chimeric 
embryos. Moreover, both eXEN and CeXEN cells are competent to be reprogrammed to 
the pluripotent state by the second step of chemical reprogramming cocktail, indicating 
their stringent similarity in their cell biological characteristics. It has been shown that the 
knockdown of the endoderm-associated TFs such as Gata6 compromises the first step 
of chemical reprogramming, whereas its overexpression with additional TF Sall4 
replaces some components of the first step chemical reprogramming cocktail, 
confirming the functional importance of the XEN-like state as an intermediate (Zhou et 
al., 2010). 
XEN-like state is an intermediate of the chemical reprogramming, but not of TF-
mediated reprogramming. Some small molecules have demonstrated the ability to 
replace individual Yamanaka factors; however, no single combination of small 
molecules is capable of replacing them all.  Intrigued by this dubious discovery, Shu et 
al. (2013) performed many studies to discern the chemical-based reprogramming 
mechanism.  They proposed a new “Seesaw” model in which the pluripotent state is a 
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precarious balancing equilibrium that results from continuous mutual competition 
between rival lineage specification forces.  Pluripotency-inducing reprogramming factors 
have been identified primarily from pluripotency-associated factors in ESC; however, 
pluripotency can be induced with lineage specifiers that suppress ESC identity using 
pluripotency rivals, most of which are not enriched in ESCs.  To that end, Shu et al. 
(2013) reported that Oct-4 and Sox-2 can be replaced by lineage specifiers that are 
involved in mesendodermal (ME) and ectodermal (ECT) specification, respectively. Oct-
4 and its substitutes attenuated the elevated expression of a group of ECT genes, 
whereas Sox-2 and its substitutes curtailed a group of ME genes during reprogramming. 
Moreover, they found that the two counteracting lineage specifiers could synergistically 
induce pluripotency in the absence of both Oct-4 and Sox-2 (Shu et al., 2013).  Based 
on these findings, they concluded that chemical-based reprogramming is mediated by 
the counteracting lineage specifier compounds, VC6FTZ.  
Insight into the mechanisms that govern nuclear reprogramming has propelled 
the advancement and improvement of reprogramming strategies.  Therefore, we sought 
to assess the genetic and epigenetic effects of pre-treatment with small molecules on 
the core pluripotency-determining transcription factors, Oct-4, Nanog, and Sox-2.   In 
this first study, we measured the effect of small molecule treatment on Oct-4, Nanog, 
and Sox-2 transcript expression in bovine fetal fibroblast (BFF) cells.   
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Materials and Methods 
Experiment 1 Experimental Design 
In the present study, we assessed the effect of pre-treatment with small molecule 
inhibitors on the expression of Oct-4, Nanog, and Sox-2 in BFF cells.  BFF cells were 
allowed to expand in culture before being split evenly into two groups.  Cells in the 
control group were cultured in complete culture medium (DMEM + 10% FBS + 1% P/S), 
whereas cells in the treatment group were cultured in complete culture medium 
supplemented with 0.5mM PD0325901, 3mM CHIR99021, and 1.8mM NuP0178 for the 
duration of 7 days.  On day 7, mRNA was isolated from control and treatment cell 
cultures for gene expression analysis. Quantitative (qRT-PCR) was performed to 
measure transcript levels for Oct4, Nanog, and Sox-2  in control and treatment BFF 
cells.  
Experiment 2 Experimental Design 
To explore what, if any, effects a longer period of treatment with PD325901, 
CHIR99021, and NuP0178 has on Oct-4, Nanog, and Sox-2 expression in BFF cells, we 
extended the culture period to 14 days.  Using the same design and procedures as 
Experiment 1, control and treatment cells were cultured in their respective culture 
system for a total of 14 days.   On day 14, mRNA was isolated from both control and 
treatment cell cultures for gene expression analysis. Quantitative (qRT-PCR) was 
performed to measure transcript levels for Oct4, Sox2, Nanog in control and treatment 
BFF cells.  
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Establishment of Cell Lines and Maintenance 
 Target cell lines were obtained from previously isolated primary cultures.  
Primary cultures of fibroblast cells were established from bovine fetuses approximately 
50 days old according to protocol (Giraldo et al., 2009; Coley, 2010).  BFF cells were 
cultured in complete culture medium composed of Dulbecco’s Modified Eagle Medium 
(DMEM) with high glucose, 10% fetal bovine serum (FBS), and 1% 
penicillin/streptomycin (P/S).  Once cells reached 80% confluency, cultures were 
passaged by releasing cells with trypsin (0.25%).  BFF cells were then resuspended in 
DMEM supplemented with 10% bovine calf serum (CS) and 10% dimethyl sulfoxide 
(DMSO) for cryopreservation.  Cryovials containing approximately 1,000,000 BFF cells 
suspended in solution were cooled at 1°C/min until reaching -80°C before storage in 
liquid nitrogen.   
 BFF cells were thawed as needed at room temperature for 30 sec, followed by 
submersion in a 37°C water bath.  Cells were then washed in complete culture medium 
and seeded at a density of 0.7 x 106  into 25-cm2 flasks and cultured under 5% CO2 and 
90% humidity at 37°C.  Because the experimental procedure required a high volume of 
cells, BFF cells were expanded through repeated passaging until a sufficient number of 
cells were obtained prior to each experiment.   
Treatment with Small Molecules 
 Chemical treatment consisted of 3 small molecule inhibitors (3i): PD0325901 
(Stemgent,Lexington, MA, Cat.no. 04-0006), a mitogen activated protein kinase/ERK 
kinase (MEK) inhibitor; CHIR99021 (Stemgent, Lexington, MA, Cat.no. 04-0004), a 
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glycogen synthase kinase-3 (GSK3) inhibitor; and NuP0178 (NuPotential, Baton Rouge, 
LA), a G9a histone methyltransferase inhibitor. A 10mM stock solution of each inhibitor 
was prepared by dissolving the crystalline solid in DMSO.  3i+ media was prepared by 
diluting each stock into complete culture medium (DMEM, 10% FBS, 1% P/S) to a 
concentration of 0.5µM PD0325901; 3µM CHIR99021; 1.8µM NuP0178.  The 
concentrations of CHIR99021 and PD0325901 utilized were consistent with previous 
studies (Yu et al., 2011) and NuP0148 concentration was estimated due to its recent 
development and concentration evaluation experiments carried out by NuPotential, LLC.   
Once BFF cells were expanded to an adequate quantity, trypsin (0.25% EDTA) 
was added to confluent cultures of BFF cells to disaggregate cells adherent to the flask, 
which were then counted using a hemocytometer.  Cells were then divided evenly into 
treatment and control groups, approximately 2.5 x 106 cells per group.  Control cells 
were resuspended in complete culture medium and split evenly between three 25-cm2 
flasks (approximately 0.7 x 106   per flask).  Similarly, treatment cells were resuspended 
in 3i+ media and split evenly between three 25-cm2 flasks (approximately 0.7 x 106   per 
flask).  All flasks were then placed in 37°C incubator with 5% CO2 and 90% humidity.  
Media was changed every 1-2 days, and cells were passaged as needed.  
Isolation of mRNA 
 On days 7 and 14, both treatment and control cells were harvested by 
trypsinization and washed in 1 ml of Dulbecco’s Phosphate Buffered Solution (DPBS) 
with Ca+2 and Mg+2.  Cells were pelleted by centrifugation, and the cell pellet was placed 
in -80°C  freezer for later use.  mRNA was isolated from both treatment and control cells 
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using Dynabeads® mRNA Direct™ Kit (Invitrogen Dynal As, Oslo, Norway, Cat.no. 
610.11/610.12) as described previously by Wrenzycli et al (2001).  Frozen cell pellets 
were removed from -80°C  freezer, and 1.25 ml of lysis/binding buffer (100 mM Tris-HCl 
(pH 7.5), 500 mM LiCl, 10 mM EDTA (pH 8), 1% lithium dodecylsulfate (LiDS), and 5 
mM dithiothreitol (DTT)) was immediately added to the frozen cell pellet.  Cell 
suspension was repeatedly passaged through a pipette tip to facilitate lysis; however 
because samples contained more than 5 x 105 cells, a DNA-shear step was also 
performed.  DNA was sheared by forcing the lysate through using a 21 gauge needle 
five times to obtain complete cell lysis.  Next, the sample lysate (1.25 ml) was added to 
250 µl of pre-washed Dynabeads® Oligo(dT)25 and resuspended completely.  The bead-
lysate mixture was incubated for 5 min on a rotating mixer to allow the polyA tail of the 
mRNA to hybridize to the oligo (dT)25 on the beads.  The beads were separated from 
the mix using a Dynal MPC-E-1 magnetic separator.  The beads/mRNA complex was 
then washed twice in 1 ml of Washing Buffer A (10 mM Tris-HCl (pH 7.5), 150 mM LiCl, 
1 mM EDTA, and 0.1% LiDS), followed by two washes with 1 ml of Washing Buffer B 
(10 mM Tris-HCl (pH 7.5), 150 mM LiCl, and 1 mM EDTA).  mRNA was eluted from the 
beads by adding 25 µl of 10 mM Tris-HCl (pH 7.5) and incubating for 2 min at 75°C.  
Immediately after incubation, tubes were placed in the Dynal MPC-E-1 magnetic 
separator to separate the beads from the mRNA.  The supernatant containing the 
mRNA was transferred to a new RNase-free tube and placed on ice for succeeding use 
in reverse transcription.   
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Reverse Transcription 
 The freshly-isolated mRNA was reverse transcribed into cDNA in a total volume 
of 25 µl using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Inc., Hercules, CA, 
USA, Cat.no. 1708890).  Each 25 µl iScript RT Reaction mix consisted of 12.5 µl of 
sample mRNA, 1 µl of reverse transcriptase, 4 µl of 5X iScript reaction mix, and 7 µl of 
nuclease-free H2O.  The reaction was conducted at 25˚C for 5 min, 42˚C for 30 min, a 
denaturation step of 85˚C for 5 min, and a final holding temperature of 4˚C.   
Quantitative Real-Time PCR 
  Our laboratory has previously analyzed BFF cells for Oct-4, Nanog, and Sox-2 
expression, thus we have validated the specificity of primers for PAP, Oct-4, Nanog, 
and Sox-2 (Coley, 2010).  All primers were designed from bovine gene sequences using 
the Beacon Designer 4.0 (PREMIER Biosoft International) (Table 3.2), and were diluted 
to 10 mM concentration.  cDNA was amplified using SsoFast™ EvaGreen supermix (Bio- 
Rad Laboratories, Inc., Hercules, CA, USA). The total 20 μl real time PCR mix consisted 
of 2 μl of cDNA, 10 µl of SsoFast™ EvaGreen Supermix, 6 μl of nuclease-free water,  
and 1 μl of forward and reverse primer pairs (10 mM) for each gene.  Within each qRT-
PCR plate setup, reactions for the reference gene and each gene of interested were 
performed using the calibrator cDNA, the sample cDNA, and a no template negative 
control.  Oct-4, Nanog, and Sox-2 expression levels in all samples was quantified using 
the Bio-Rad CFX Connect™ Real-Time PCR Detection System.  The PCR program 
used for the amplification of all genes consisted of a denaturing cycle of 30 sec at 95°C; 
40 cycles of PCR (95°C for 5 sec and 55°C for 20 sec); ); a melting curve analysis 
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which consisted of 95°C for 5 sec, 65°C for 1 min, followed by continuous acquisition at 
97˚C, with 5 acquistions per ˚C; and a final holding temperature of 4°C. 
Data was quantified using the method for relative quantification in qRT-PCR 
described by Pfaffl (2001).  Values are reported as relative transcription or the n-fold 
difference relative to a calibrator. A mixture of cDNA from BFF cells at multiple 
passages was used as a calibrator for all of the target genes.  PAP was used as the 
internal reference gene. The threshold cycle value of the reference gene was used to 
normalize the target gene signals in each sample. The amount of target transcripts 
relative to the calibrator was calculated using the following equation: n-fold difference = 
Efficiency Target GeneΔCTT/ Efficiency Reference GeneΔCTR, where an efficiency value 
of two was assumed.  The ΔCTT (for the target gene) value was calculated by 
subtracting the sample CT value of the target gene from the calibrator CT value of the 
Table 3.1. Primer Sets for qRT-PCR for Gene Expression Analysis 
 
Gene 
Accession 
Number 
Primers 
Amplicon 
Length 
Oct-4 NM174580 
Sense GGTTCTCTTTGGAAAGGTGTTC 
Antisense ACACTCGGACCACGTCTTTC 
 
223 
Nanog DQ069776 
Forward AATTCCCAGCAGCAAATCAC 
Reverse CCCTTCCCTCAAATTGACAC 
 
215 
Sox-2 NM001105463 
Sense AGGACTGAGAGAAAGAAGAAGAG 
Antisense AAGAAAGAGGCAAACTGGAATC 
 
164 
PAP X63436 Sense AAGCAACTCCATCAACTACTG 
Antisense ACGGACTGGTCTTCATAGC 
169 
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target gene. The ΔCTR (for the reference gene) value was calculated by subtracting the 
sample CT value of the reference gene PAP from the calibrator CT value of the 
reference gene. Therefore, all target abundance levels were expressed as n-fold 
differences relative to a calibrator and normalized to the reference gene in order to 
compensate for PCR variations between runs.   
Statistical Analysis 
 In this experiment, a completely random design with repeated measures was 
employed to assess any effect treatment with 3i+ media had on Oct-4, Nanog, and Sox-
2 gene expression in BFF cells over time.  The PROC MIXED with repeated measures 
analysis with autoregression of order one covariance was used in SAS statistical 
software to determine any statistical differences in relative gene expression between 
treatment and control groups over time.  
Results 
 The values corresponding to the relative expression of Oct-4, Nanog, and Sox-2 
in untreated BFF cells and BFF treated with 3i+ media at day 7 and day 14 are reported 
in tables 3.3 and 3.4, respectively.  Statistical analysis comparing Oct-4, Nanog, and 
Sox-2 expression levels in treatment and control groups revealed no significance 
difference in gene expression between groups at either day 7 or day 14.  Likewise, time 
did not have a significant effect on Oct-4, Nanog, and Sox-2 transcript levels in BFF 
cells cultured in the presence of the small molecule inhibitors, CHIR99021, PD0325901, 
and NuP0178.  Therefore, there was no significant effect of the treatment and time 
interaction.  
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1The relative expression of Oct-4, Nanog, and Sox-2 at day 7 was measured in five BFF 
cell lines, designated as BEZ 2, BEZ 3, BEX 4, BEX 1, and BEX 3.  BEZ 2 served as a 
biological replicate, denoted as BEZ 2 (1) and BEZ 2 (2). 
 
 
 
 
Sample Oct-4 Nanog Sox-2 
BEZ 2 P4 CON (1) 20311.37 8364.13 474.41 
BEZ 2 P4 TRMT (1) 14.83 1.75 4.59 
BEZ 3 P4 CON  0.2793 0.9931 0.0151 
BEZ 3 P4 TRMT 1.68 0.1199 0.0100 
BEZ 2 P4 CON (2) 76.64 21.26 9.71 
BEZ 2 P3 TRMT (2) 4.41 0.3686 0.1550 
BEX 4 P3 TRMT 235.57 11.88 8.28 
BEX 1 P3 CON 1.56 0.6242 0.0813 
BEX 3 P4 CON (2) 3.92 2.53 0.1708 
Table 3.2.  Oct-4, Nanog, and Sox-2 Relative Expression in Treatment and 
Control BFF Cells on Day 71 
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2The relative expression of Oct-4, Nanog, and Sox-2 at day 14 was measured in three 
BFF cell lines, designated as BEZ 2, BEZ 3, and BEX 4.  BEZ 3 served as a biological 
replicate, denoted as BEZ 3 (1) and BEZ 3 (2). 
 
Discussion 
 The small molecule inhibitors, CHIR99021 and PD325901, have been widely 
used as tools to facilitate the generation and maintenance of iPSC (Li et al., 2009; Lin et 
al., 2009; Hanna et al., 2010; Zhou et al., 2010).  In these cases, CHIR99021 and 
PD325901 aid in overcoming the “roadblocks” encountered during the reprogramming 
process by inducing the necessary epigenetic modifications needed to silence the 
somatic cell genome and completely reactivate the ESC genome.  Interestingly, 
CHIR99021 and PD0325901 have been found capable of maintaining mESC in culture 
without the need of feeder cells or exogenous cytokines (Buehr et al., 2008).  Inhibition 
of both the GSK3 and MEK pathways by CHIR99021 and PD0325901, respectively, 
Sample Oct-4 Nanog Sox-2 
BEZ 2 P5 CON  51063.33 5404.70 14066.74 
BEZ 2 P4 TRMT  209.39 51.63 30.70 
BEZ 3 P5 CON  0.8409 0.9593 10.3388 
BEZ 3 P5 TRMT (1) 1.23 0.6690 0.6690 
BEX 4 P6 TRMT 9.32 2.16 0.5946 
BEZ 3 P5 TRMT (2) 7.11 8.51 4.41 
Table 3.3. Oct-4, Nanog, and Sox-2 relative expression in treatment and control BFF 
cells on day 142 
 
Table 3.3. Oct-4, Nanog, and Sox-2 relative expression in treatment and control BFF 
cells on day 142 
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eliminates the need for LIF and BMP in mESCs.  Stimulation of the ERK signaling 
pathway triggers the transition from pluripotency to lineage-commitment (Kunath et al., 
2007); therefore, by blocking the ERK signaling pathway, lineage-commitment is 
inhibited and the ground state of ESC self-renewal is maintained.  Suppression of ERK 
activation is achieved with the addition of PD0325901, and together with CHIR99021, 
have shown to be sufficient to sustain efficient ESC self-renewal (Ying et al., 2008).   
We have previously shown that some sources of ASC, including BFF, express 
transcripts for the key pluripotency genes, Oct-4, Nanog, and Sox-2 (Coley, 2007).  
While these cell types’ differentiating and self-renewing capabilities are far less robust 
than that of ESC, we reasoned that the same system involved in promoting the 
pluripotent state in mESC and hESC would similarly work to maintain, or possibly 
enhance, the less differentiated state characteristic of BFF cells.  While there was no 
significant increase in Oct-4, Nanog, or Sox-2 relative gene expression detected 
between control and treatment samples at either day 7 or day 14, it is important to note 
that there was no significant decrease in the relative expression of these transcripts 
over time either.  Typically, pluripotent gene expression in ASC decreases as passage 
number increases (Tsai and Hung, 2012), yet the extended culture period and 
consequential passaging required to maintain cells in culture for an extended period of 
time did not result in a significant decrease in Oct-4, Nanog, or Sox-2 expression.   
This is an opportune time to point out that not all researchers agree that 
CHIR99021 and PD032591 facilitate somatic cell reprogramming.  Several studies 
dissecting the mechanism of action of CHIR99021 and PD032591 in facilitating and 
enhancing nuclear reprogramming have been previously discussed in detail (Li et al.; 
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Buehr et al., 2008; Shi et al., 2008b; Ying et al., 2008; Li et al., 2009; Nichols and Smith, 
2009; Hanna et al., 2010; Zhou et al., 2010; Tsutsui et al., 2011), and while there is no 
shortage of evidence supporting this, it is imperative to discuss those results conflicting 
with this notion.  As previously discussed, the Wnt signaling pathway is postulated to 
play an important role in self-renewal in both human and mouse ESC.  When the 
canonical Wnt signaling pathway is stimulated, β-catenin translocates to the nucleus 
where it interacts with Tcf/Lef proteins to activate target genes.  With regards to nuclear 
reprogramming, the Wnt-β-catenin pathway is thought to help reestablish pluripotency 
specifically by alleviating the inhibitory effect of T-cell factor 3 (TCF3) on pluripotency 
(Grigoryan et al., 2008; Niwa, 2011).  CHIR99021 has been shown to enable the 
production of iPSC from MEF cells through its’ effect on Wnt signaling which leads to 
the overexpression of Oct-4 and Klf-4 (Li et al., 2009).  The other school of thought is 
that the Wnt-β-catenin pathway actually induces cellular differentiation.  A 2012 study by 
researchers at the Institute for Stem Cell and Regenerative Medicine and the Howard 
Hughes Medical Institute proposed a revised interpretation of the role of  Wnt-β-catenin 
signaling in hESC, which supports a primary role for Wnt-β-catenin signaling in 
differentiation, rather than self-renewal of hESC in culture.  Davidson and colleagues 
reported long-term expansion of hESC was possible with sustained inhibition of the 
Wnt-β-catenin signaling pathway, indicating that Wnt-β-catenin signaling is not required 
for undifferentiated hESC proliferation. Furthermore, they also found that Oct-4 
functionally represses endogenous Wnt-β-catenin signaling in self-renewing hESC 
(Davidson et al., 2012).  Lian and colleagues came to the same conclusion when they 
demonstrated that activation of the Wnt-β-catenin signaling pathway via CHIR990021 
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promoted the differentiation, not self-renewal, of hESC into cardiomyocytes (Lian et al., 
2012).  
 More recently, the effects of PD0325091 and CHIR99021 on the induction of 
endogenous pluripotency genes in reprogrammed iPSC in porcine were investigated.  
Transfected porcine fetal fibroblast cells were treated with the two small molecule 
inhibitors (2i), and then examined for the activation of pluripotency markers in the fetal 
fibroblast cells during their conversion to iPSC by measuring alkaline-phosphatase (AP) 
expression.  Researchers found that there were significantly fewer AP-positive colonies 
compared with cells cultured in medium supplemented only with LIF.  Moreover, 
endogenous expression of pluripotency-related genes, including Oct-4, Nanog, and 
Sox-2, was significantly lower in 2i-treated cell cultures (Petkov et al., 2014).  Other 
studies have similarly reported a decrease in the expression of key pluripotency genes, 
particularly Oct-4, in cells cultured with PD0325091 and CHIR99021 in porcine (Telugu 
et al., 2011; Gao et al., 2013).  These findings cast doubt on the effectiveness of these 
small molecule inhibitors in the reprogramming of somatic cells to pluripotency in 
species other than the mouse and human, opening up the possibility that PD0325091 
and CHIR99021 may be ineffective on bovine cells.  While further research is necessary 
before any conclusions should be made, the results of these studies taken together with 
the findings of this study suggest that the cow may differ from the mouse and human in 
terms of pluripotent pathways.   
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CHAPTER IV 
EPIGENETIC EFFECTS OF TREATMENT WITH SMALL MOLECULE 
INHIBITORS ON BOVINE FETAL FIBROBLAST CELLS 
 
Introduction 
The discovery of an increasing number of chemical compound that either induce 
or enhance nuclear reprogramming has revealed the basic mechanisms underlying the 
reprogramming process.  Based on their mechanism of action, these chemical 
compounds fall broadly into several classes, including those that modulate (1) 
epigenetic protein activity, (2) signal transduction pathways, (3) transcription factor 
activity, and (4) cell metabolism (Li et al.).  CHIR99021 is among those small molecules 
that modulate signal transduction pathways.  CHIR99021 is a potent and selective 
inhibitor or GSK3, inhibiting both GSK3β and GSK3α.  GSK3 is a serine/threonine 
kinase that is a key inhibitor of the Wnt signaling pathway.  Because CHIR99021 inhibits 
GSK3, it functions as a Wnt activator (Bain et al., 2007).  The Wnt signaling pathway 
plays an important role in self-renewal in both human and mouse ESC.  When the 
canonical Wnt signaling pathway is stimulated, β-catenin translocates to the nucleus 
where it interacts with Tcf/Lef proteins to activate target genes.  With regards to nuclear 
reprogramming, the Wnt-β-catenin pathway is thought to help reestablish pluripotency 
specifically by alleviating the inhibitory effect of T-cell factor 3 (TCF3) on pluripotency 
(Grigoryan et al., 2008; Niwa, 2011).  CHIR99021 has been shown to enable the 
production of iPSC from MEF cells through its’ effect on Wnt signaling which leads to 
the overexpression of Oct-4 and Klf-4 (Li et al., 2009).  Likewise, CHIR99021 has been 
found capable of substituting for c-myc (Marson et al., 2008).   
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Successful nuclear reprogramming requires several highly-complex processes 
and mechanisms be carried out methodically.  Gene expression profiling and RNA 
interference (RNAi) screening in MEF revealed three phases of nuclear reprogramming: 
initiation, maturation, and stabilization (Figure 4.1).  Studies showed that the first phase, 
initiation, is characterized by a mesenchymal-to-epithelial transition (MET) that is driven 
by BMP signaling (Samavarchi-Tehrani et al., 2010),  and that the repression of the 
pluripotency transgenes is required for the transition from the maturation phase to the 
stabilization phase (Li et al., 2010; Golipour et al., 2012).  Genome-wide analysis of 
intermediate cells poised to become iPSC revealed that the reprogramming process 
encompasses two distinct waves of major gene activity.  The first wave occurs between 
day 0 and day 3, and is characterized by the activation of genes responsible for 
proliferation, metabolism, cytoskeleton organization, and the downregulation of genes 
associated with development.  The second wave of major gene activity occurs towards 
the end of the 12 day reprogramming process, after day 9, and is characterized by the 
expression of genes responsible for embryonic development and stem cell 
maintenance.  It is at this stage that the core pluripotency-regulating network is 
activated and the pluripotent state is stabilized (Polo et al., 2012).  Complimentary 
studies using single-cell techniques for quantifying gene expression in cells that 
undergo complete nuclear reprogramming towards pluripotency indicated that induction 
of reprogramming factors provokes stochastic gene expression changes in a subset of 
pluripotency genes early in the reprogramming process.  These stochastic changes  
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Figure 4.1. Phases of the Reprogramming Process.  In the model described by 
Buganim et al. (2013), the reprogramming process is divided into two phases: a long 
`stochastic' phase of gene activation followed by a shorter hierarchical more 
`deterministic' phase of gene activation that begins with the activation of the Sox2 
locus. After induction, the four factor reprogramming cocktail, OSKM, initiates 
stochastic gene expression, and fibroblasts assume one of several possible fates 
(such as, apoptosis, senescence, transformation, transdifferentiation or 
reprogramming). In the early phase, reprogrammable cells will increase proliferation, 
undergo changes in histone modifications at somatic genes, initiate MET, and 
activate DNA repair and RNA processing (Samavarchi-Tehrani et al., 2010).  The 
reprogrammable cells then enter an intermediate phase with an unknown rate-
limiting step that delays the conversion to iPSCs and contributes to the long latency 
of the process. In this phase, cells undergo a stochastic activation of pluripotency 
markers, a transient activation of developmental regulators, and activation of 
glycolysis (Li et al., 2010; Golipour et al., 2012).  In general the transcriptional 
changes in this phase are small. In some rare cases, the stochastic gene expression 
will lead to the activation of "predictive markers" such as Utf1, Esrrb, Dppa2, and 
Lin28, which ultimately activate Sox-2.  Activation of Sox-2, either directly or 
indirectly by these markers, initializes the second phase of reprogramming by 
triggering a series of deterministic events that ultimately results in iPSC. In this late 
phase, the cells eventually stabilize into the pluripotent state as the transgenes are 
silenced, the cytoskeleton is remodeled to an ESC-like state, the epigenome is 
reset, and the core pluripotency circuitry is activated (Polo et al., 2012).   
 
Figure 4.1. Phases of the Reprogramming Process.  In the model described by 
Buganim et al. (2013), the reprogramming process is divided into two phases: a long 
`stochastic' phase of gene activation followed by a shorter hierarchical more 
`deterministic' phase of gene activation that begins with the activation of the Sox2 
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occur in tandem with MET and other events characteristic of the initiation phase, and 
are essential for cells to transition to the next phase (Li et al., 2010).  Unlike the 
firstphase, the second phase is believed to be a more deterministic phase of gene 
activation, in which the core pluripotency circuitry is activated and the pluripotent state is 
stabilized in cells. Very few cells make the transition to the second phase, however, as 
the majority become trapped in an intermediate phase between the first and second 
phases.  The low efficiency of iPSC production is thought to be due to a rate-limiting 
stochastic event that is a precursor to the second phase of reprogramming (Buganim et 
al., 2012).    
The epigenetic changes accompanying successful nuclear reprogram include 
chromatin reorganization, DNA demethylation of promoter regions of key pluripotency-
associated genes, reactivation of the somatically silenced X chromosome, and genome-
wide resetting of histone posttranslational modifications (Takahashi et al., 2007; 
Maherali and Hochedlinger, 2009).  While some of these processes, such as X 
chromosome reactivation, occur late in the reprogramming process, changes in histone 
modifications can be observed immediately after factor induction (Koche et al., 2011), 
suggesting that alterations in histone marks are an early event that is associated with 
initiation of the reprogramming process (Buganim et al., 2013).  The roles of relevant 
histone marks during the reprogramming process are summarized in Table 4.1.  The 
first of these changes to be observed is a peak of de novo deposition of H3K4me2 at 
the promoter and enhancer regions of many pluripotency-associated genes, including 
Sall4 and Fgf4, which are enriched for Oct-4 and Sox-2 binding sites and lack H3K4me1 
or H3K4me3 marks.  Concomitantly, the promoters of genes responsible for the somatic  
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Histone Mark Function Phase of 
Reprogramming 
in which Change 
Occurs 
Example of 
Change 
H3K4me2 Marks promoters 
and enhancers 
Early phase Decrease at MEF 
and EMT genes; 
increase at 
proliferation, 
metabolism, 
pluripotency, and 
MET genes 
H3K4me3 Marks active loci Early phase Increase at 
proliferation and 
metabolism genes 
H3K27me3 Marks repressed 
loci 
Early phase Increase at MEF 
and EMT genes 
H3K4me1 Marks enhancers Early phase Increase at 
proliferation and 
metabolism genes 
H3K36me3 Marks 
transcriptionally 
active regions 
Early to middle 
phase 
Increase at early 
and late 
pluripotency genes 
H3K9me3 Marks 
heterochromatin 
regions 
Late phase Decrease at late 
pluripotency genes 
H3K36me2 Marks potential 
regulatory regions 
(such as newly 
transcribed genes) 
Early phase Increase at early 
pluripotency genes 
H3K79me2 Marks 
transcriptionally 
active regions 
Early to middle 
phase 
Decrease at MEF 
and EMT genes 
Table 4.1. Roles of Relevant Histone Marks during Nuclear Reprogramming 
(Buganim et al., 2013)  
 
Table 4.1. Roles of Relevant Histone Marks during Nuclear Reprogramming 
(Buganim et al., 2013)  
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cell program being to lose H3K4me2 (Koche et al., 2011).  Chromatin reorganization 
from the somatic state to an ESC-like one is required for the activation of the 
pluripotency circuitry system.  It appears that the chromatin reorganization events take 
place in a coordinated and sequential manner. Rearrangement of the heterochromatin, 
characterized by the presence of H3K9me3 and heterochromatin protein 1, precedes 
the activation of Nanog, while enrichment of euchromatin marks occurs concurrently 
with Nanog activation (Mattout et al., 2011).  Taking into consideration the epigenetic 
changes in histones in iPSC, H3 is the histone researched the most, as it is directly 
related to genes expressed during embryonic development, such as Oct-4, Nanog, and 
Sox-2.  Methylation of H3K27 is associated with the suppression of various genes, and 
persistent H3K27me3 blocks reprogramming.  However, methylation of H3K4 is 
associated with the activation of different embryonic genes.  Termed “bivalent domains”, 
these are regions enriched for repressive H3K27me3 and simultaneously for activating 
H3K4me3 (Mikkelsen et al., 2007).  Bivalent domains were initially thought to be ESC-
specific, however, Mikkelsen and colleagues (2007) showed that bivalent domains are 
more indicative of genes that exist in a poised state.   Genes that harbor the bivalent 
domain are transcriptionally silenced in ESCs, suggesting a potentially dominant role of 
H3K27me3 (Maherali and Hochedlinger, 2009). In ESCs genes with bivalent domain 
include a substantial number of differentiation-related genes targeted by the core 
pluripotency factors.  The bivalent domain on the promoters of these genes allows for a 
quick response to differentiation cues.  As ESC begin to differentiate, most bivalent 
genes lose one of the marks, leaving either the repressive mark H3K27me3 or the 
activating mark H3K4me3 (Mikkelsen et al., 2007; Pan et al., 2007; Zhao et al., 2007). It 
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should be noted that the significance of bivalent domains in key developmental genes 
has recently been brought into question.  Bivalent domains are not a universal feature of 
pluripotent cells, nor are they unique to pluripotent cells (Mikkelsen et al., 2007).  Mouse 
ES cells can be maintained in a naïve state in the absence of serum by MEK and GSK3 
inhibitors (2i).  A recent study by Marks and colleagues showed that mouse ESC grown 
in 2i medium, compared to serum-cultured mouse ESC,  exhibit highly similar H3K4me3 
profiles, but substantially reduced prevalence of H3K27me3, resulting in significantly 
fewer bivalent domains.  In spite of this, these genes are still effectively silenced (Marks 
et al., 2012).  Therefore, another mechanism must contribute to the repression of these 
loci, and a large proportion of bivalent domains in ES cells cultured in serum are due to 
acquisition of H3K27me3 at promoters (Marks et al., 2012; Liang and Zhang, 2013; 
Chen and Dent, 2014).   
H3K9 methylation is associated with transcription silencing and heterochromatin 
formation. Genome-wide localization studies have shown that the genomic domains 
marked with H3K9me3 are substantially expanded in differentiated cells compared with 
ESC (Hawkins et al., 2010).   H3K9 methylation has been identified as the key barrier to 
the acquisition of pluripotency following nuclear reprogramming, as it has been shown 
to determine cell fate between pre-iPSC and iPSC.  It is thought that the switch between 
euchromatin and heterochromatin is dependent upon the balance between H3K9 
methylation and demethylation (Chen et al., 2013).  As ESC differentiate, G9a, a H3K9-
specific HMT, contributes to silencing the Oct-4 locus by establishing a heterochromatin 
state.  Conversely, H3K9 histone demethylases (HDM) are essential to maintaining 
ESC identity (Loh et al., 2007).  Although H3K9 methylation has been dubbed the 
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primary hindrance to fully reprogrammed iPSC, mechanistic insights into the role H3K9 
methylation plays in the epigenetic reprogramming of cell fate lends H3K9 methylation 
to be a tangible barrier to reprogramming, capable of being overcome.  This decreasing 
the levels of H3K9 methyltransferases or overexpressing H3K9 demethylases enhances 
the efficiency of iPSC production (Kubicek et al., 2007; Loh et al., 2007; Shi et al., 
2008a; Shi et al., 2008b; Huang et al., 2010).   
Unlike ESC which are detected only in the ICM of a blastocyst, adult stem cells 
(ASC) are found in a variety of adult mammalian tissues and organs.  ASC primarily 
function to replenish damaged cells within these tissues and organs as a result of 
normal cellular senescence or injury (Odorico et al., 2001).  The differentiation potential 
ASC has long been thought to be limited to cell lineages present in the organ from 
which they are derived; however, several studies have challenged this notion by 
demonstrating that some ASC exhibit a particularly high degree of plasticity.  Unlike 
terminally differentiated somatic cells, the less differentiated state of ASC can assume 
the functional phenotypes and expression profiles of cells unique to other tissues 
(Herzog et al., 2003).  Furthermore, we and other groups have reported the presence of 
Oct-4, Nanog, and Sox-2 expression in some sources of ASC in the cow, mouse, and 
pig (Kues et al., 2005; Carlin et al., 2006; Coley, 2007).  These findings support the 
notion that ASC less differentiated than other somatic cell types, and share some 
characteristics with ESC, including epigenomic regulatory program.  While the 
chromatin of ASC is globally less in an open configuration than that of ESC, a common 
set of “stemness genes”, including regulators of chromatin, transcription, cell cycle and 
survival is marked by H3K4me3, and is active in both mouse hair follicle stem cells (HF-
63 
 
SC) and ESC (Lien et al., 2011).  In hematopoietic stem cells (HSC), H3K4me3 is more 
prevalent compared to differentiated cells types, and enhancers of differentiation genes 
are marked by monomethylation of H3K4, H3K9, and H3k27, which is likely involved in 
maintaining activation potential required for differentiation  (Cui et al., 2009).    
Once established, cellular identity is remarkably stable.  Chromatin modifications 
are faithfully inherited from cell division to cell division, highlighting the major hurdles 
iPSC must overcome in order to be fully reprogrammed to pluripotency.  The use of 
small molecule compounds that target chromatin modifications and/or specific signaling 
pathways have proven to be effective at overcoming these reprogramming hurdles.  
Considering the significance of H3K4, H3K9, and H3K27 methylation in the 
determination of cell fate, we sought to assess the effects of pre-treatment with small 
molecules on these histone modifications at the promoter regions of Oct-4, Nanog, and 
Sox-2.  
Materials and Methods 
Experimental Design 
BFF cells were cultured in the presence of three small molecule inhibitors (3i): 
PD0325901, a mitogen activated protein kinase/ERK kinase (MEK) inhibitor; 
CHIR99021, a glycogen synthase kinase-3 (GSK3) inhibitor; and NuP0178 
(NuPotential, Baton Rouge, LA), a G9a histone methyltransferase inhibitor, for a total of 
14 days.  On day 7 and day 14, cells were fixed using 37% formaldehyde solution, and 
harvested for the preparation of chromatin using sonication shearing.  The resulting 
chromatin was then immunoprecipitated with antibodies directed against H3K4me3, 
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H3K9me3, and H3K27me.  Following immunoprecipitation, DNA was recovered and 
analyzed by qRT-PCR to identify DNA loci associated with H3K4me3, H3K9me3, and 
H3K27me3 on Oct-4, Nanog, and Sox-2.  
Establishment of Cell Lines and Maintenance 
 Target cell lines were obtained from previously isolated primary cultures.  
Primary cultures of fibroblast cells were established from bovine fetuses approximately 
50 days old according to protocol (Giraldo et al., 2009).  These Bovine Fetal Fibroblast 
(BFF) cells were cultured in complete culture medium composed of Dulbecco’s Modified 
Eagle Medium (DMEM) with high glucose, 10% fetal bovine serum (FBS), and 1% 
penicillin/streptomycin (P/S).  Once cells reached 80% confluency, cultures were 
passaged by releasing cells with trypsin (0.25%).  BFF cells were then resuspended in 
DMEM supplemented with 10% bovine calf serum (CS) and 10% dimethyl sulfoxide 
(DMSO) for cryopreservation.  Cryovials containing approximately 1,000,000 BFF cells 
suspended in solution were cooled at 1°C/min until reaching -80°C before storage in 
liquid nitrogen.   
 BFF cells were thawed as needed at room temperature for 30 sec, followed by 
submersion in a 38°C water bath.  Cells were then washed in complete culture medium 
and seeded at a density of 0.7 x 106  into 25-cm2 flasks and cultured under 5% CO2 and 
90% humidity at 37°C.  Because the experimental procedure required a high volume of 
cells, BFF cells were expanded through repeated passaging until a sufficient number of 
cells were obtained prior to each experiment.   
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Treatment with Small Molecules 
 Chemical treatment consisted of 3 small molecule inhibitors (3i): PD0325901, a 
mitogen activated protein kinase/ERK kinase (MEK) inhibitor; CHIR99021, a glycogen 
synthase kinase-3 (GSK3) inhibitor; and NuP0178 (NuPotential, Baton Rouge, LA), a 
G9a histone methyltransferase inhibitor. A 10mM stock solution of each inhibitor was 
prepared by dissolving the crystalline solid in DMSO.  3i+ media was prepared by 
diluting each stock into complete culture medium (DMEM, 10% FBS, 1% P/S) to a 
concentration of 0.5µM PD0325901; 3µM CHIR99021; 1.8µM NuP0178.  The 
concentrations of CHIR99021 and PD0325901 utilized were consistent with previous 
studies (Yu et al., 2011) and NuP0148 concentration was estimated due to its recent 
development and concentration evaluation experiments carried out by NuPotential, LLC.   
Once BFF cells were expanded to an adequate quantity, trypsin (0.25% EDTA) 
was added to confluent cultures of BFF cells to disaggregate cells adherent to the flask, 
which were then counted using a hemocytometer.  Cells were then divided evenly into 
treatment and control groups, approximately 2.5 x 106 cells per group.  Control cells 
were resuspended in complete culture medium and split evenly between three 25-cm2 
flasks (approximately 0.7 x 106   per flask).  Similarly, treatment cells were resuspended 
in 3i+ media and split evenly between three 25-cm2 flasks (approximately 0.7 x 106   per 
flask).  All flasks were then placed in 37°C incubator with 5% CO2 and 90% humidity.  
Media was changed every 1-2 days, and cells were passaged as needed.  
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Cell Fixation and Shearing 
On days 7 and 14, cells grown in a T-75 culture flask were harvested for chromatin 
immunoprecipitation (ChIP) procedures using ChIP-IT® Express Magnetic Chromatin 
Immunoprecipitation Kit & Sonication Shearing Kit (Active Motif, 53008).  The existing 
culture medium was removed from flasks, and 20 ml of freshly-prepared Fixation 
Solution, composed of 37% formaldehyde and complete culture medium (540 µl 37% 
formaldehyde + 20 ml complete culture medium), was added to fix protein/DNA 
interactions.  Cells were incubated on a shaking platform for 10 min at RT, and then 
washed in ice-cold 1X PBS solution.  To stop the fixation reaction, 10 ml Glycine Stop 
Fix Solution (1 ml 10X Glycine Buffer+ 1 ml 10X PBS + 8 ml dH2O) was added to each 
flask and incubated on a shaking platform for 5 min at RT.  Cells were washed in ice-
cold 1X PBS solution, and 5 ml of ice-cold Cell Scraping Solution (dH2O with 10% 10X 
PBS) with 30 µl 100 mM PMSF was added to each flask.  Adherent cells were dislodged 
by thoroughly scraping the bottom of the culture flask with a rubber policeman.  Cells 
were collected in a 15 ml conical tube held on ice, and then pelleted by centrifugation at 
720 x g for 10 min at 4°C.  After discarding the supernatant, 1 µl 100 mM PMSF and 1 
µl PIC were added to the pellet and placed in -80°C freezer until use in sonication step.   
Due to the nature of the experimental condition, growth and survival of cell 
cultures for an extended period of time proved to be quite difficult. We found that cells 
did best when they were maintained in smaller culture vessels (T-25) throughout the 
experiment.   In this case, cells were harvested on day 7 and 14 by trypsinization, and 
washed in 1 ml of Dulbecco’s Phosphate Buffered Solution (DPBS) with Ca+2 and Mg+2.  
Cells were then resuspended in Fixation Solution (1 ml per 1-2 x 106  cells) and allowed 
67 
 
to incubate for 10 min.  In-suspension fixation was stopped by the addition of 10% 10X 
Glycine.  Cells were pelleted by centrifugation at 720 x g for 5 min at 4°C, and 
immediately washed in ice-cold 1X PBS solution.  After discarding the supernatant, 1 µl 
100 mM PMSF and 1 µl PIC were added to the pellet and placed in -80°C freezer until 
use in sonication step.   
Optimization of Chromatin Shearing by Sonication 
Chromatin shearing conditions can vary greatly depending on the cell type and 
the treatment in the experiment; therefore, shearing conditions must be optimized for 
these factors specific to this experiment.  To do this, BFF cells were grown to 70-80% 
confluency in two 15 cm plates under standard cell culture conditions (DMEM, 10% 
FBS, 1% P/S; 37°C, 5% CO2).  When the cells were ready to be harvested, the existing 
culture medium was aspirated from the plates, and 20 ml of freshly-prepared Fixation 
Solution, composed of 37% formaldehyde and complete culture medium (540 µl 37% 
formaldehyde + 20 ml complete culture medium), was added to each plate to fix 
protein/DNA interactions.  The plates were placed on a shaking platform for 10 min at 
RT, and then washed in 10 ml ice-cold 1X PBS solution.  The fixation reaction was 
stopped by adding 10 ml Glycine Stop-Fix Solution (1 ml 10X Glycine Buffer+ 1 ml 10X 
PBS + 8 ml dH2O) to each plate.  The plates were incubated on a shaking platform for 5 
min at RT, and then washed in 10 ml ice-cold 1X PBS solution.  Immediately before 
use, 60 µl 100 mM PMSF was added to 12 ml of ice-cold Cell Scraping Solution (5.4 ml 
dH2O + 600 µl 10X PBS).  5 ml of Cell Scraping Solution was added to each plate, and 
cells were scraped down the plate using a rubber policeman.  Cells from both plates 
were collected and pooled together in a 15 ml conical tube and pelleted by 
68 
 
centrifugation.  After aspirating the supernatant, 1 µl 100 mM PMSF and 1 µl PIC was 
added to the cell pellet and placed in a -80°C freezer overnight in order to best replicate 
sample conditions.  The next day, the cell pellet was thawed on ice and resuspended in 
3 ml ice-cold Lysis Buffer (ChIP-IT Express Kit, Active Motif 53008) supplemented with 
15 µl PMSF and 15 µl PIC.  Following a 30 min incubation on ice, cells were transferred 
(1 ml at a time) to a dounce homogenizer and lysed on ice with 30 strokes.  The cell 
lysate was collected in a 15 ml conical tube and pelleted by centrifugation.  The 
supernatant was discarded, and the cell pellet was resuspended in 2 ml Shearing Buffer 
(ChIP-IT Express Kit, Active Motif 53008) supplemented with 10 µl PMSF and 10 µl 
PIC.  The cell suspension was aliquoted into equal volumes in six 1.7 ml 
microcentrifuge tubes, and the tubes were placed on ice.  The six aliquots of fixed 
chromatin were sheared using Cole Parmer Ultrasonic Processor (Cole-Parmer, Vernon 
Hills, IL, USA)  (500 watts, 120 volts, 3 mm probe) at 30% amplitude using six different 
conditions: (1): 20 pulses of 20 sec, 30 sec rest; (2): 30 pulses of 20 sec, 30 sec rest; 
(3): 40 pulses of 20 sec, 30 sec rest; (4): 20 pulses of 30 sec, 30 sec rest; (5): 30 pulses 
of 30 sec, 30 sec rest; (6): 40 pulses of 30 sec, 30 sec rest.  After sonication, the tubes 
were centrifuged for 10 min at 14000 x g at 4°C, and the supernatant, containing the 
sheared chromatin, was collected and prepared into 50 µl aliquots.  One 50 µl aliquot of 
sheared chromatin from each of the six shearing conditions was subjected to cross-link 
reversal and purified according to protocol described below.  Samples were separated 
by electrophoresis through a 1% agarose gel to determine the optimal shearing 
conditions.  Optimally sheared chromatin will yield a smear between 200-1500 bp. 
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Based on this assay, we concluded that shearing using 25 pulses of 20 sec, 30 sec rest 
yielded chromatin suitable for our experimentations.  
DNA Clean Up to Assess Shearing Efficiency and DNA Concentration 
 To assess shearing efficiency as well as determine the DNA concentration, 150 
µl of dH2O was added to 50 µl of each sheared chromatin sample, followed by 10 µl 5 M 
NaCl.  The tubes were then placed in a thermocycler at 65°C overnight to reverse the 
cross-links.  The following day, the samples were removed from the thermocycler and 1 
µl RNase A (10 µg/µl) was added to each tube.  The samples were then incubated for 
15 min at 37°C.  Next, 10 µl Proteinase K (0.5 µg/µl) was added to each sample, and 
the tubes were placed in a thermocycler at 42°C to incubate for 1.5 h.  After incubation, 
DNA was cleaned up by adding 200 µl 1:1 phenol/chloroform TE saturated pH 8 (Sigma 
Aldrich, P3803) to each sample, vortexed, and centrifuged for 5 min at 14000 x g.  The 
aqueous phase was then transferred to a new microcentrifuge tube, and 20 µl 3 M 
Sodium Acetate pH 5.2 (Sigma-Aldrich, S2889) followed by 500 µl 100% ethanol was 
added to each sample.  1 µl glycogen (20 µg/µl) (ThermoFisher Scientific, 10814010) 
was also added to each sample to act as carrier for DNA in order to improve recovery.  
The tubes were vortexed and placed in -20°C freezer overnight to permit DNA 
precipitation.  The next day, the tubes were centrifuged for 10 min at 14000 x g at 4°C 
to separate the precipitate from the supernatant.  After removing the supernatant, the 
pellet was washed in 500 µl 70% ice cold ethanol and centrifuged again at 14000 x g for 
5 min in a 4°C microcentrifuge.  The supernatant was carefully removed, and the pellet 
was allowed to air-dry before resuspension in 30 µl dH2O.  DNA concentration was 
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measured using a Thermo Scientific™ NanoDrop 2000 Spectrophotometer (Wilmington, 
DE, USA).  
Shearing by Sonication 
 Previously frozen pellets of cross-linked cells were thawed on ice, resuspended 
in 1 ml of ice-cold Lysis Buffer supplemented with 5 µl PIC + 5 µl PMSF, and held on ice 
for 30 min to initiate cell lysis.  The cell suspension was then transferred to a glass 
pestle on ice for Dounce Homigenization.  Cell lysis was monitored under phase 
contrast microscopy after every 10 strokes until the nuclei were sufficiently released 
(between 20 and 40 strokes).  The cells were then transferred to a 1.7 microcentrifuge 
tubes and centrifuged at 720 x g for 10 min at 4°C.  After discarding the supernatant, 
the nuclei pellet was resuspended in 300 µl Shearing Buffer (ChIP-IT Express Kit, 
Active Motif 53008) supplemented with 1.5 µl PIC and 1.5 µl PMSF.  DNA was sheared 
using Cole Parmer Ultrasonic Processor (Cole-Parmer, Vernon Hills, IL, USA) (500 
watts, 120 volts, 3 mm probe) under the optimal conditions determined for the BFF cells 
used in this experiment (25 pulses of 20 sec, 30 sec rest).  After sonication, the sheared 
chromatin was separated from the cellular debris by centrifugation at 14000 x g for 10 
min at 4°C and prepared into 50 µl aliquots.  One aliquot was immediately used for 
assessing DNA shearing efficiency and determining the DNA concentration.  The 
remaining aliquots of sheared chromatin were stored at -80°C for later use.   
Chromatin Immunoprecipitation 
 Previously frozen aliquots of sheared chromatin were thawed on ice.  Once 
thawed, 10 µl was removed and processed as “Input DNA”.  Chromatin 
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Immunoprecipitation (ChIP) reactions were set up in siliconized 1.7 ml microcentrifuge 
tubes using reagents provided in ChIP-IT® Express Kit (Active Motif, 53052), with the 
exception of the antibodies. Antibodies for H3K4me3 (Active Motif, 39915), H3K9me3 
(Active Motif, 39765), H3K27me3 (Active Motif, 39155) were reconstituted to a 
concentration of 1 µg/µl and added as the final component of the ChIP reaction.  First, 
the volume of sheared chromatin needed for each reaction was calculated based on the 
DNA concentration that was previously determined.  For reactions using less than 60 µl 
of chromatin, 25 µl Protein G Magnetic Beads, 10 µl ChIP Buffer 1, 1 µl PIC, and 3 µg of 
antibody were added to the appropriate volume of sheared chromatin and brought up to 
a final volume of 100 µl with dH2O.  For reactions requiring more than 60 µl of 
chromatin, 25 µl Protein G Magnetic Beads, 20 µl ChIP Buffer 2, 2 µl PIC, and 3 µg of 
antibody were added to the appropriate volume of sheared chromatin and brought up to 
a final volume of 200 µl with dH2O.  Chromatin was immunoprecipitated by incubating 
the reactions on an end-to-end rotator overnight at 4°C.  The beads were separated 
from the supernatant using a magnetic stand, and quickly washed once in 800 µl ChIP 
Buffer 1, followed by two washes in 800 µl ChIP Buffer 2.  Chromatin was eluted by 
incubating the beads in 50 µl Elution Buffer AM2 for 15 min at RT on an end-to-end 
rotator.  50 µl Reverse Cross-linking Buffer was mixed with the eluted chromatin.  After 
the beads were separated, the supernatant was transferred to a fresh PCR tube, and 
both the ChIP and Input DNA samples were incubated at 95°C for 15 min.  2 µl 
Proteinase K (0.5 µg/µl) was added to each tube and successively incubated at 37°C for 
1 h.  Lastly, 2 µl Proteinase K Stop Solution was added to each sample.   
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Chromatin Immunoprecipitation DNA Purification 
 Before ChIP samples can be used in PCR, the DNA must be purified away from 
the components and contaminants present in an eluted ChIP sample.  Chromatin IP 
DNA Purification Kit (Active Motif, 58002) was used to purify DNA in all ChIP samples.  
To each sample, 5 volumes DNA Purification Binding Buffer was added for every one 
volume of sample.  Next, 5 µl 3 M Sodium Acetate (pH 5.2) was added to determine the 
solution had a pH less than 7.5.  Samples were then briefly centrifuged, and the DNA 
was captured by a DNA Purification Column.  Column-bound DNA was washed with 
750 µl Wash Buffer, and the flow through was discarded.  Following another brief spin in 
order to remove any residual Wash Buffer from the column, the column was transferred 
to a new 1.7 microcentrifuge tube, and the DNA was eluted using 50 µl DNA Purification 
Elution Buffer.   
Quantitative Real-Time PCR 
 The methylation status of the promoter regions of Oct-4, Nanog, and Sox-2 in 
both untreated and 3i+ BFF cells at day 7 and 14 was analyzed using Bio-Rad CFX 
Table 4.2. Primer sets for qRT-PCR for Quantification of Target Enrichment 
Gene Primer Sequence 
Oct-4                          Forward TGGGTCGGGAGGGTTAGAGT 
                         Reverse CAACAACTCACTCGCCTCCTC 
Nanog Forward AGGGATTGAAGGTTATTTGTTTT 
  Reverse TATCCAAACATCCAAAAATTAAAA 
Sox-2   Forward GCGTTTTTTTTTTTATTTTAGTAGT 
                        Reverse ACTTTCCCCCTTTTACAAACA 
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Connect™ Real-Time PCR Detection System.  The PCR primers designed to amplify 
the promoter regions of these genes were previously validated by (Huang et al. (2014)).  
We confirmed the specificity of these primer sequences (Table 4.2) through RT-PCR 
followed by gel electrophoresis using calibrator cDNA produced from a pool of bovine 
genomic DNA.  Reactions were carried out in a total volume of 20 µl, which consisted of 
10 µl SsoFast™ EvaGreen® Supermix (Bio Rad, 1725201), 1 µl forward and reverse 
primer pairs (10 mM), 6 µl DEPC H2O, and 2 µl sample DNA.  Reaction mixes were  
concocted for each ChIP DNA sample, Input DNA, No Ab control sample, and a no 
template negative control for all three genes.  The PCR program used for the 
amplification of all genes consisted of a denaturing cycle of 2 min at 94°C; 40 cycles of 
PCR (94°C for 30 sec, 52ºC for 40 sec, 72ºC for 30 sec, 72ºC for 7 min).   
ChIP-qPCR data must be normalized for sources of variability, including amount 
of chromatin, efficiency of immunoprecipitation, and DNA recovery.  Data in this study 
was normalized using the Percent of Input Method.  The Percent of Input Method 
assumes that the ChIP qPCR signals are directly related to the amount of input 
chromatin.  Therefore, these values must be adjusted for using the following equation: 
ΔCt [normalized ChIP] = (Ct [ChIP] - (Ct [Input] - Log2 (Input Dilution Factor), where 
Input Dilution Factor= (fraction of the input chromatin saved)-1.  Once the adjusted input 
value was calculated for each gene in each sample, the normalized ΔCt for each ChIP 
sample was calculated.  Finally, the percent of input (Input %) for each sample is 
calculated as follows: Input % = 100/2 (ΔCt [normalized ChIP).  Data in this study is presented 
as a percentage of the input, representing the enrichment of precipitated DNA 
associated with either H3K4me3, H3K9me3, or H3K27me3 relative to the input sample.    
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Statistical Analysis 
In this experiment, a completely random design with repeated measures was 
employed to assess any effect treatment with 3i+ media had on the methylation status 
of H3K4, H3K9, and H3K27 at Oct-4, Nanog, and Sox-2 promoter regions over time. 
The PROC MIXED with repeated measures analysis with autoregression of order one 
covariance was used in SAS statistical software to determine any statistical differences 
H3K4, H3K9, and H3K27 enrichment at Oct-4, Nanog, and Sox-2 promoters relative to 
the input between treatment and control groups over time. 
Results 
 The PROC MIXED with repeated measures analysis with autoregression of order 
one covariance was used to determine the effect of treatment, time, and the 
treatment*time interaction has on trimethylation of H3K4, H3K9, and H3K27 on the 
promoters of Oct-4, Nanog, and Sox-2 in untreated BFF cells and 3i+ treated BFF cells 
over time (Tables 4.2. – 4.7). For each effect, p-value ≤ 0.05 indicates a significant 
difference exists.  The treatment* time interaction was found to have a significant effect 
on the methylation status of H3K4 in Nanog (p = 0.02), as well as H3K9 in Oct-4 (p = 
0.05).  Additionally, time was determined to have a significant effect on H3K27 
methylation in Sox-2 (p = 0.04) (Figures 4.2 – 4.4).  No significant difference in 
enrichment was detected in Oct-4 H3K4, Oct-4 H3K27, Nanog H3K9, Nanog H3K27, 
Sox-2 H3K4, Sox-2 H3K9 as an effect of treatment, time, or treatment*time interaction.    
75 
 
   
  
Sample Oct-4 H3K4me3 Oct-4 H3K9me3 Oct-4 H3K27me3 
BEZ 3 P4 CON (A) 0.0059% 0.0296% 0.0449% 
BEX 1 P3 CON 0.0631% 0.7239% 0.4944% 
BEZ 3 P4 CON (B) 0.0110% 0.0089% 0.0126% 
BEX 2 P5 CON 0.7867% 2.80% 1.30% 
BEX 3 P6 CON 1.09% 0.9618% 0.0977% 
BEZ 1 P2 CON 9.21% 11.19% 5.87% 
BEZ 2 P4 TRMT 1.05% 1.73% 1.07% 
BEX 4 P3 TRMT 0.5373% 0.6399% 0.2307% 
BEZ 1 P2 TRMT 
(A) 
3.40% 2.19% 3.82% 
BEZ 1 P2 TRMT 
(B) 
0.0546% 0.1797% 0.0761% 
Table 4.3. H3K4me3, H3K9me3, H3K27me3 Enrichment at Oct-4 promoter in 
Control and Treatment BFF cells on Day 7 
 
Table 4.3. H3K4me3, H3K9me3, H3K27me3 Enrichment at Oct-4 promoter in 
Control and Treatment BFF cells on Day 7 
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Sample Nanog H3K4me3 Nanog H3K9me3 Nanog H3K27me3 
BEZ 3 P4 CON (A) 8.96% 0.2860% 2.24% 
BEX 1 P3 CON 0.2291% 27.55% 13.77% 
BEZ 3 P4 CON (B) 177.77% 1290.63% 1041.07% 
BEX 2 P5 CON 5.91% 2.13% 19.50% 
BEX 3 P6 CON 1.34% 0.7494% 0.4016% 
BEZ 1 P2 CON 2.92% 1.75% 5.29% 
BEZ 2 P4 TRMT 8.13% 1.54% 3.15% 
BEX 4 P3 TRMT 3.49% 1.00% 1.46% 
BEZ 1 P2 TRMT 
(A) 
52.12% 59.05% 34.63% 
BEZ 1 P2 TRMT 
(B) 
0.8373% 3.30% 8.19% 
Table 4.4. H3K4me3, H3K9me3, H3K27me3 Enrichment at Nanog promoter in 
Control and Treatment BFF cells on Day 7 
 
Table 4.4. H3K4me3, H3K9me3, H3K27me3 Enrichment at Nanog promoter in 
Control and Treatment BFF cells on Day 7 
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Sample Sox-2 H3K4me3 Sox-2 H3K9me3 Sox-2 H3K27me3 
BEZ 3 P4 CON (A) 331.73%% 42.93% 2.56% 
BEX 1 P3 CON 437.72% 1.19% 0.4216% 
BEZ 3 P4 CON (B) 4.10% 35.60% 0.4809% 
BEX 2 P5 CON 0.2650% 0.6480% 0.2405% 
BEX 3 P6 CON 0.2438% 0.2022% .05601% 
BEZ 1 P2 CON 0.0772% 0.2920% 1.02% 
BEZ 2 P4 TRMT 1.71% 0.1712% 19.34% 
BEX 4 P3 TRMT 0.3826% 0.8373% 0.0880% 
BEZ 1 P2 TRMT 
(A) 
0.8201% 4.51% 0.7922% 
BEZ 1 P2 TRMT 
(B) 
0.1084% 1.18% 0.2438% 
Table 4.5. H3K4me3, H3K9me3, H3K27me3 Enrichment at Sox-2 promoter in 
Control and Treatment BFF cells on Day 7 
 
 
Table 4.5. H3K4me3, H3K9me3, H3K27me3 Enrichment at Sox-2 promoter 
in Control and Treatment BFF cells on Day 7 
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Sample Oct-4 H3K4me3 Oct-4 H3K9me3 Oct-4 H3K27me3 
BEZ 2 P5 CON 0.1011% 0.2022% 3.04% 
BEZ 3 P5 CON (A) 1.18% 0.6992% 0.0022% 
BEZ 1 P4 CON 0.0622% 0.4245% 0.1712% 
BEZ 2 P5 TRMT 3.35% 8.30% 3.37% 
BEZ 3 P5 TRMT 6.12% 22.38% 34.15% 
BEX 4 P6 TRMT 5.18% 4.77% 4.77% 
Sample Nanog H3K4me3 Nanog H3K9me3 Nanog H3K27me3 
BEZ 2 P5 CON 175.32% 118.92% 3.35% 
BEZ 3 P5 CON (A) 16.27% 1.36% 7.80% 
BEZ 1 P4 CON 7.38% 2.32% 11.91% 
BEZ 2 P5 TRMT 3.42% 2.68% 1.80% 
BEZ 3 P5 TRMT 723110.30% 184576.10% 616549.07% 
BEX 4 P6 TRMT 1.96% 65.98% 93.30% 
Table 4.6. H3K4me3, H3K9me3, H3K27me3 Enrichment at Oct-4 promoter in 
Control and Treatment BFF cells on Day 14 
 
Table 4.6. H3K4me3, H3K9me3, H3K27me3 Enrichment at Oct-4 promoter in 
Control and Treatment BFF cells on Day 14 
Table 4.7. H3K4me3, H3K9me3, H3K27me3 Enrichment at Nanog promoter in 
Control and Treatment BFF cells on Day 14 
 
Table 4.7. H3K4me3, H3K9me3, H3K27me3 Enrichment at Nanog promoter 
in Control and Treatment BFF cells on Day 14 
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Sample Sox-2 H3K4me3 Sox-2 H3K9me3 Sox-2 H3K27me3 
BEZ 2 P5 CON 5.83% 3.24% 9.54% 
BEZ 3 P5 CON (A) 6.60% 3.82% 4.09% 
BEZ 1 P4 CON 0.8032% 0.2860% 0.0930% 
BEZ 2 P5 TRMT 1.16% 16.04% 69.74% 
BEZ 3 P5 TRMT 1.26% 7.13% 0.3002% 
BEX 4 P6 TRMT 3.37% 100.69% 27.74% 
Table 4.8. H3K4me3, H3K9me3, H3K27me3 Enrichment at Sox-2 promoter in 
Control and Treatment BFF cells on Day 14 
 
Table 4.8. H3K4me3, H3K9me3, H3K27me3 Enrichment at Sox-2 promoter 
in Control and Treatment BFF cells on Day 14 
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Figure 4.2. ChIP followed by qRT-PCR was used to examine H3K4me3, 
H3K9me3, and H3K27me3 enrichment at the promoter region of Oct-4 in BFF 
cells treated with and without PD0325901, CHIR99021, and NuP0178 (3i) at day 7 
and day 14.  Enrichment is expressed as a ratio of immunoprecipitated DNA over 
input DNA.  Percent of Input was calculated using the following equation: Input % 
= 100/2 (ΔCt [normalized ChIP), where ΔCt [normalized ChIP] = (Ct [ChIP] - (Ct [Input] - 
Log2 (Input Dilution Factor).  This data is presented in Table 4.2. and Table 4.5. 
The interaction between time and treatment was observed to have a significant 
effect on H3K9me3 enrichment at the Oct-4 promoter (p = 0.05), and is illustrated 
above.   
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Figure 4.3. ChIP followed by qRT-PCR was used to examine H3K4me3, H3K9me3, 
and H3K27me3 enrichment at the promoter region of Nanog in BFF cells treated with 
and without PD0325901, CHIR99021, and NuP0178 (3i) at day 7 and day 14.  
Enrichment is expressed as a ratio of immunoprecipitated DNA over input DNA.  
Percent of Input was calculated using the following equation: Input % = 100/2 (ΔCt 
[normalized ChIP), where ΔCt [normalized ChIP] = (Ct [ChIP] - (Ct [Input] - Log2 (Input 
Dilution Factor).  This data is presented in Table 4.2. and Table 4.5. The interaction 
between time and treatment was observed to have a significant effect on H3K4me3 
enrichment at the Nanog promoter (p = 0.02), and is illustrated above.   
 
82 
 
 
 
 
 
 
0
5
10
15
20
25
30
35
Day 7 Day 14
P
er
ce
n
t 
o
f 
In
p
u
t
Sox-2 
H3K27 Enrichment
Control Treatment
Figure 4.4. ChIP followed by qRT-PCR was used to examine H3K4me3, H3K9me3, 
and H3K27me3 enrichment at the promoter region of Sox-2 in BFF cells treated with 
and without PD0325901, CHIR99021, and NuP0178 (3i) at day 7 and day 14.  
Enrichment is expressed as a ratio of immunoprecipitated DNA over input DNA.  
Percent of Input was calculated using the following equation: Input % = 100/2 (ΔCt 
[normalized ChIP), where ΔCt [normalized ChIP] = (Ct [ChIP] - (Ct [Input] - Log2 (Input 
Dilution Factor).  This data is presented in Table 4.2. and Table 4.5. Time was 
observed to have a significant effect on H3K27me3 enrichment at the Sox-2 
promoter (p = 0.04), and is illustrated above.   
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Discussion 
 The aim of this experiment was to determine what, if any, effect treatment of BFF 
cells with a small molecule inhibitor cocktail comprised of CHIR99021, PD0325901, and 
NuP0178 has on the methylation levels of H3K4, H3K9, and H3K27 on the promoters of 
the core pluripotency-associated genes, Oct-4, Nanog, and Sox-2.  Building upon this 
design, we expanded our query to determine what, if any, effect the length of treatment 
has on the methylation status of these histone residues.  Generally methylation of H3K4 
is associated with transcriptional activation, whereas methylation of H3K9 and H3K27 is 
mainly associated with transcriptional repression.  Several small molecules, affecting 
specific signaling pathways and/or chromatin modifications, have been shown to 
improve both the kinetics and efficiency of reprogramming (summarized in Table 
3.1)(Zhang et al., 2012). These chemical modifiers aid in overcoming the “roadblocks” 
encountered during the reprogramming process by inducing the necessary epigenetic 
modifications needed to silence the somatic cell genome and completely reactivate the 
ESC genome. Chemical treatment of cells prior to reprogramming can remodel the 
epigenetic landscape of the somatic cell type to be more like that of ESC by removing  
the repressive epigenetic marks characteristic of somatic cells and relaxing chromatin 
structure to allow the reprogramming factors easier access to target genes.  It has been 
suggested that the genome of less differentiated cells may be more amenable to 
reprogramming or require less reprogramming following the induction of pluripotency 
either by SCNT or another experimental strategy (Rideout et al., 2001). Currently, the 
overall efficiency of SCNT is between 0-3% (number of live offspring as a percentage of 
the number of nuclear transfer embryos) (Paterson et al., 2003).  While several factors 
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have been identified as contributors to the inefficiency of the procedure, incomplete 
epigenetic reprogramming is considered the primary reason for developmental failure of 
SCNT embryos (Li et al., 2003).  Based on this notion, we hypothesized that treatment 
with CHIR99021, PD0325901, and NuP0178 (3i) will remodel the epigenetic landscape 
of BFF cells via histone modifications so that they may ultimately be more easily 
reprogrammed by means such as SCNT.  
To examine the effect of 3i treatment on histone methylation at the lysine 4, 9, 
and 27 residues in Oct-4, Nanog, and Sox-2, we utilized ChIP, a powerful and popular 
tool for understanding the mechanisms of gene regulation by transcription factors and 
modified histones.  Using antibodies that recognize a specific protein or protein 
modification of interest, ChIP determines the relative abundance of that protein or 
protein modification of interest at one or more locations in the genome.  ChIP is the 
most widely used procedure for the examination of histone modification, and it has 
proven to yield very valuable information on chromatin-associated processes in 
numerous species.  Nevertheless, the technique must be optimized by each investigator 
in their model system specific.  Optimization of cell harvesting, the cross-linking of 
chromatin, sonication conditions, and qRT-PCR setup and analysis of ChIP-enriched 
genomic DNA is very tedious, challenging, and time-consuming.  Indeed, this proved to 
be true for this research project.  We originally used enzymatic digestion, rather than 
sonication, to shear chromatin for ChIP because it is said to greatly simplify and 
streamline the ChIP protocol, as well as reduce disruption of protein/DNA complexes 
traditionally caused by sonication. Unfortunately, enzymatic shearing proved to be 
ineffective in our model system, leading us to conclude that BFF may be among those 
85 
 
cell types more resistant to cell lysis.  We changed our ChIP protocol from enzymatic 
shearing to mechanical shearing of chromatin by sonication.  Optimization of the 
amended ChIP protocol included the individual optimization of many variables including, 
cell harvesting technique, cell fixation time, cell lysis by dounce homogenization, 
sonication conditions, and qRT-PCR setup and analysis of the ChIP material. The ChIP 
protocol optimized for our model system and implemented in this study is described in 
Appendix A.  
BFF cells from seven different cell lines were cultured with and without 
CHIR99021, PD0325901, and NuP0178 for a total of 14 days.  Using the optimized 
ChIP protocol established for our model system, chromatin was prepared from these 
cultures on day 7 and day 14. The resulting chromatin was then immunoprecipitated 
with antibodies directed against H3K4me3, H3K9me3, and H3K27me.  Following 
immunoprecipitation, DNA was recovered and analyzed by qRT-PCR to identify DNA 
loci associated with these histone modifications at the promoters of Oct-4, Nanog, and 
Sox-2.  Enrichment of precipitated DNA associated with either H3K4me3, H3K9me3, or 
H3K27me3 is represented as a percentage of the input (Table 4.2 and Table 4.3).  ChIP 
followed by qRT-PCR revealed that a great deal of variability in H3K4, H3K9, and 
H3K27 trimethylation of Oct-4, Nanog, and Sox-2 exists between samples.  This is seen 
in both control and treatment cells at both time points.  This variability can be attributed 
to several different factors, including the method used for normalizing the ChIP data.   
The two most common ways to normalize data is the Fold Enrichment method 
and the Percent of Input method.  The Fold Enrichment method of normalization 
assumes the level of background signal reproducible between different primer sets, 
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samples, and replicate experiments.  Fold Enrichment is calculated by taking the ChIP 
signal and dividing it by the No antibody signal, representing the ChIP signal as a fold 
increase relative to the background signal.  Conversely, the Percent of Input method of 
normalization takes the ChIP signal and divides it by the signal measured from the input 
sample.  The input sample is a positive control that does not go through the 
immunoprecipitation process, correlating to the total available promoters in the 
chromatin.  It is indicative for the presence and amount of chromatin used in the ChIP 
reaction.  It is assumed that the obtained ChIP and No antibody signal levels are directly 
related to the amount of input chromatin  (Haring et al., 2007).  After thoroughly 
researching these two methods of normalization, we concluded that the Percent of Input 
method was the best method of normalization for this experiment.  Because background 
signal levels do vary between primer sets, samples, and experiments, the assumption of 
the Fold Enrichment method- the level of background signal is reproducible between 
different primer sets- often results in a random over- or under-representation of the 
ChIP data (Haring et al., 2007).  While we contend that the Percent of Input method is 
the optimal method of data normalization, it also has its drawbacks.  The main 
disadvantage of this method is caused by differences in handling the input and ChIP 
samples.  Because the input sample is taken so early in the preparation process, it is 
subjected to many opportunities for unequal handling, possibly rendering the input and 
ChIP samples different from one another.  There is no consensus on how to normalize 
ChIP-qPCR data within the literature because there is no perfect method of 
normalization.  While the Percent of Input method is the preferred method of 
normalization for the majority of recent studies, the inherent nature of the procedure 
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subjects data to potential variability, which could possibly be the reason for the 
variability observed in this study.  Lastly, it is important to remember that enrichment of 
a target is not solely dependent on the quantity on the antigen associated with it.  
Immunoprecipitation is affected by the accessibility of that antigen in that particular 
chromatin environment, the affinity of the antibody and the precise conditions of the 
immunoprecipitation process.  For this reason, the level of enrichment is always 
expressed as a ratio of the precipitated sequence over the input.  Therefore, the 
absolute levels of different antigens present in the same sequence cannot be compared 
directly to one another.   
Our previous examinations of Oct-4, Nanog, and Sox-2 transcript levels in 
sources of ASC, including BFF, revealed capricious expression of these transcripts 
between replicates (Coley, 2007).  Taking this into consideration may help explain the 
variability in enrichment of H3K4me3, H3K9me3, and H3K27me3 at the promoter 
regions of these transcripts between samples.  Furthermore, the molecular mechanisms 
determining the turnover rate of histone modifications can influence data interpretation 
(Clayton et al., 2006).  Particular histone modifications can exist as very transient 
marks, including methylation of H3K4 (Morillon et al., 2005).  When a particular histone 
modification has a high turnover rate, only a subset of the crosslinked nucleosomes will 
carry that modification, resulting in a lower ChIP signal than when that same 
modification is continuously present (Haring et al., 2007).  
While the scarcity of stem cells in most tissues remains a major challenge in 
studying adult stem cells, several groups were able to isolate sufficient quantities of 
adult stem cells from tissues to conduct transcriptional and epigenetic profiling studies. 
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Results from the limited number of studies presently available support the notion that 
the chromatin states of adult stem cells are intermediate between those of pluripotent 
cells and terminally differentiated cells. For example, while the chromatin of adult stem 
cells is globally less `open' compared with that of ES cells, a common set of stemness 
genes, including regulators of chromatin, transcription, cell cycle and survival, is marked 
by H3K4me3 and is active in both HF-SCs and ES cells (Lien et al., 2011).  In HSCs, 
H3K4me3 is more prevalent compared with differentiated progeny, and enhancers of 
differentiation genes are marked by monomethylation of H3K4, H3K9, and H3K27, 
which is likely involved in the maintenance of activation potential required for 
differentiation.  Specifically, gene expression positively correlates with H3K4me3, 
H3K4me1, H3K9me1, H3K36me3, and H4K20me1 and negatively correlates with 
H3K9me3 and H3K27me3 (Cui et al., 2009; Chen and Dent, 2014).   
It is important to note that Marks et al. (2012) demonstrated that mouse ESC 
grown in media containing CHIR99021 and PD0325901 exhibit similar H3K4me3 
profiles, but substantially reduced prevalence of H3K27me3 at promoters, many less 
bivalent domains, and lower- rather than higher- expression of lineage-specific genes, 
compared to those cells grown in culture-containing medium.  Therefore, a large 
proportion of bivalent domains in ESC cultured in serum are due to the acquisition of 
H3K27me3 at promoters (Marks et al., 2012; Chen and Dent, 2014). 
Transcription factors preferentially bind to `open' chromatin. Thus, epigenetic 
mechanisms may set the stage for lineage-specific transcription factors by creating and 
maintaining a permissive chromatin environment. Indeed, an emerging theme from 
recent studies is that epigenetic pre-patterning occurs before cell fate decisions. In one 
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study, Szutorisz and colleagues (2005) differentiatied mouse ES cells toward the B-cell 
lineage and investigated the epigenetic regulation of gene expression. They found that 
a cis-acting element in the immunoglobulin lambda-like polypeptide 1 (Igll1; also known 
as λ5)–pre-B lymphocyte gene 1 (VpreB1) locus is marked by histone H3ac and 
H3K4me2 at a discrete site in undifferentiated ES cells. The marked region expands 
during differentiation and becomes a localized center for transcription factors and RNA 
polymerase II recruitment before full activation of the Igll1 and VpreB1 genes at the pre-
B cell stage (Szutorisz et al., 2005) Similarly, Xu et al. (2011) showed that the liver and 
pancreas regulatory elements have distinct chromatin patterns in undifferentiated 
endoderm cells.  When the cells differentiate into hepatoblasts, acetylation of H3K9 and 
H3K14 promote expression of hepatic genes, and H3K27me3 appears to repress the 
expression of pancreatic genes (Xu et al., 2011).  The concept of transcriptional priming 
by chromatin changes is reinforced by recent studies of higher-order chromatin 
structure during induced `dedifferentiation'. Circular chromosome conformation capture 
with high-throughput sequencing (4C-seq) reveals that, during somatic cell 
reprogramming into iPSC, the establishment of long-range interchromosomal 
interactions with the Oct-4 and Nanog loci precedes transcriptional activation of these 
genes (Apostolou et al., 2013; Wei et al., 2013; Chen and Dent, 2014).   BFF treated 
with CHIR99021, PD0325901, and NuP0178 may ultimately be more easily 
reprogrammed by means such as SCNT than other somatic cells that have not 
undergone pre-treatment with small molecules because they may “prime” BFF cells for 
nuclear reprogramming by inducing epigenetic changes permissible to nuclear 
reprogramming. While we cannot exclude that the significant effects observed in this 
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experiment are simply the result of randomness, we cannot exclude that they may in 
fact be due to the effects of treatment with these three small molecules priming BFF 
cells for nuclear reprogramming.  
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CHAPTER V 
THE EFFECT OF CHIR99021 AND PD325901 TREATMENT ON 
PLURIPOTENT TRANSCRIPT EXPRESSION AND HISTONE 
ACETYLATION IN BOVINE FETAL FIBROBLAST CELLS 
Introduction 
Attempts to derive iPSC from livestock species have been met with limited 
success.  Although there have been reports of reprogramming somatic cells towards 
pluripotency in livestock species, such as the pig, cow, and buffalo (Huang et al., 2011; 
West et al., 2011; Deng et al., 2012), almost all of the reported livestock iPSC were not 
capable of forming germ line chimeras.  Differences in ESC and iPSC properties 
between the mouse and the human have been well documented, as these have been 
studied the most.  Similarly, studies in other mammalian species, include the cow, pig, 
and rat, for example, have shown clear differences in preimplantation development, 
embryonic transcript expression patterns, and the conditions required to maintain 
proliferative and undifferentiated cells in culture (Telugu et al., 2010).   Even in the 
mouse and human, gene expression networks that support pluripotency and 
proliferation are still not completely understood, although it is clear that two or more 
signal transduction pathways, probably acting in parallel must exist to account for the 
different cell types.  While it is likely that some version of these pathways also support 
ESC identity in ungulate systems, it is thought that the cell signaling pathways 
underlying pluripotency and nuclear reprogramming may differ across species; 
therefore, the effectiveness of certain reprogramming techniques and enhancement 
strategies may vary cross species (Telugu et al., 2010).  Because the correct 
expression profile of pluripotency-related genes is critical for the derivation and 
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maintenance of pluripotent cells, it is necessary to identify the specific molecular 
machinery regulating pluripotency in the bovine in order to create iPSC from this 
species.   
A number of small molecule compounds have been reported to facilitate and/or 
enhance iPSC production in a variety of species.  CHIR99021 and PD325901 (2i) has 
been widely used to enhance to reprogramming in the mouse and human (Li et al., 
2009; Lin et al., 2009; Hanna et al., 2010; Zhou et al., 2010; Li et al., 2011; Marks et al., 
2012).  For this reason, 2i has been adopted into reprogramming systems in other 
species as well.  However, its effectiveness in mammalian species other than the 
mouse and human has been brought into question as some studies in the pig have 
shown reduced pluripotent gene expression in 2i-treated cells (Telugu et al., 2011; Gao 
et al., 2013; Petkov et al., 2014).  It is possible that the molecular network responsible 
for establishing and maintaining pluripotency in the pig may differ from that in the mouse 
and human.  This could similarly be the case for other mammalian species, including 
bovine.  Therefore, the effectiveness of 2i treatment on bovine somatic cell types needs 
to be assessed to determine if it is suitable for the pre-treatment of donor cells for 
SCNT. Because less-differentiated cell types are more readily reprogrammed than their 
terminally differentiated counterpart, it is important to ascertain if 2i maximizes 
epigenetic priming for successful reprogramming.  
An important aspect of using reprogrammed cells as donor cells for SCNT is the 
ability to treat and expand cells to a sufficient quantity.  Typically somatic cells have a 
limited proliferative capacity; therefore, it is important genetic modifications and 
subsequent preparation for SCNT be accomplished before the cells enter senescence.  
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It has previously been estimated that ~45 population doubling (PD) are required to 
transfect, select, expand, and prepare cells for SCNT.  Therefore, the longevity of donor 
cells in culture is a key parameter in the development of ideal donor cells for SCNT 
(Denning et al., 2001).  
Materials and Methods 
Experiment 1 Experimental Design 
In the present study, we assessed we assessed the individual and combinatory 
effects of CHIR99021 and PD0325901 treatment on Oct-4, Nanog, and Sox-2 relative 
expression in BFF cells over time. BFF cells were allowed to expand in culture before 
being split evenly into seven groups and treated as follows: (1) 3 µM CHIR99021 
prepared from 10 mM stock solution in DMSO (Stemgent, Lexington, MA, Cat.no. 04-
0004-02); (2) 0.5 µM PD0325901 prepared from 10 mM stock solution in DMSO 
(Stemgent, Lexington, MA, Cat.no. 04-0006-02); (3) 3 µM CHIR99021 + 0.5 µM 
PD0325901; (4) 1.5 µM CHIR99021 + 0.25 µM PD0325901; (5) 6 µM CHIR99021 + 1 
µM PD0325901; (6) complete culture medium + 0.053% DMSO; (7) 1 µM TSA prepared 
from 5 mM stock solution in DMSO (Sigma-Aldrich, T1952).  BFF cells were treated for 
a total of 14 days, and on days 7 and 14 mRNA was isolated from all cultures for gene 
expression analysis.  qRT-PCR was performed to measure transcript levels for Oct-4, 
Nanog, and Sox-2 in all BFF cell cultures.   
Experiment 2 Experimental Design 
To explore the effects of CHIR99021 and PD0325901 treatment at varying 
concentrations as mentioned above on global histone acetylation, flow cytometry was 
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performed on cells harvested from the seven treatment groups on days 7 and 14 of 
culture.  Cells were fixed, permeabilized, and incubated with anti-acetyl-histone H3 
antibody to determine the total level of H3 acetylation (H3ac) using flow cytometry.    
Experiment 3 Experimental Design 
 As previously mentioned, we have observed adverse side effects following 
treatment with 3i (CHIR99021, PD0325901, NuP0178) resulting in reduced cell survival.  
To explore the potential culprit causing this, we studied growth characteristics of cells 
cultured under the seven conditions mentioned above and calculated the population 
doublings after 7 and 14 days of treatment.   
Establishment of Cell Lines and Maintenance 
 Target cell lines were obtained from previously isolated primary cultures.  
Primary cultures of fibroblast cells were established from bovine fetuses approximately 
50 days old according to protocol (Giraldo et al., 2009).  These Bovine Fetal Fibroblast 
(BFF) cells were cultured in complete culture medium composed of Dulbecco’s Modified 
Eagle Medium (DMEM) with high glucose, 10% fetal bovine serum (FBS), and 1% 
penicillin/streptomycin (P/S).  Once cells reached 80% confluency, cultures were 
passaged by releasing cells with trypsin (0.25%).  BFF cells were then resuspended in 
DMEM supplemented with 10% bovine calf serum (CS) and 10% dimethyl sulfoxide 
(DMSO) for cryopreservation.  Cryovials containing approximately 1,000,000 BFF cells 
suspended in solution were cooled at 1°C/min until reaching -80°C before storage in 
liquid nitrogen.   
95 
 
 BFF cells were thawed as needed at room temperature for 30 sec, followed by 
submersion in a 38°C water bath.  Cells were then washed in complete culture medium 
and seeded at a density of 0.3 x 106  into 6 well plates and cultured under 5% CO2 and 
90% humidity at 37°C.   
Treatment with Small Molecules 
 Once BFF cells expanded to a sufficient quantity, cells were split into 6-well 
tissue culture dishes at a seeding density of 0.3 x 106 and treated under the appropriate 
conditions defined for the seven treatment groups.  All media was prepared with 
complete culture medium (DMEM + 10% FBS + 1% P/S) and 10 mM stock solutions of 
the small molecule inhibitors CHIR 99021 (Stemgent, Lexington, MA, Cat. No. 04-0004-
02) and PD0325901 (Stemgent, Lexington, MA, Cat. No. 04-0006-02).  Because the 
stock solutions of the small molecule inhibitors are reconstituted in DMSO, which can 
potentially be toxic to cells, DMSO was added to complete culture medium (DMEM + 
10% FBS + 1% P/S + 0.053% DMSO) to control for this possibility.  This concentration 
of DMSO used was determined based on the concentrations of CHIR99021 and 
PD0325901 in the other media preparations.  Therefore, all cells were exposed to 
DMSO at approximately the same concentration. The treatments are as follows: (1) 3 
µM CHIR99021 (CHIR); (2) 0.5 µM PD0325901 (PD); (3) 3 µM CHIR99021 + 0.5 µM 
PD0325901 (2i); (4) 1.5 µM CHIR9901 + 0.25 µM PD0325901 (2i*); (5) 6 µM 
CHIR99021 + 1 µM PD0325901(2i**); (6) 1 µM Trichostatin A (TSA); (7) DMEM + 10% 
FBS + 1% P/S + 0.053% DMSO (control).  Cells were then placed placed in 37°C 
incubator with 5% CO2 and 90% humidity.  Media was changed every 1-2 days. 
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Cell Growth Characteristics and Population Doublings 
 On days 7 and 14 cells were harvested for downstream applications, including 
qRT-PCR and flow cytometry.  Cells were tyrpsinized and washed in 1 ml of Dulbecco’s 
Phosphate Buffered Solution (DPBS) with Ca+2 and Mg+2.  Cells were counted using a 
hemacytometer to determine concentration.  The average concentration of cells from 
each culture group was calculated and used to determine population doublings (PDs).  
The following formula was used to calculate PDs: PD = 3.32 (log Xe – log Xb), where 
Xb is the cell number at the beginning of the incubation time and Xe is the cell number 
at the end of the incubation time (Patterson, 1979).  Pictures of the cells in culture were 
also taken on days 7 and 14 to compare growth characteristics of cells between 
treatments and over time.   
Isolation of mRNA 
 On days 7 and 14, both treatment and control cells were harvested by 
trypsinization and washed in 1 ml of Dulbecco’s Phosphate Buffered Solution (DPBS) 
with Ca+2 and Mg+2.  Cells were counted using a hemacytometer to determine 
concentration. Cells were pelleted by centrifugation and stored at -80° C to until 
required for RNA purification.  Because the concentration of cells harvested from 
cultures was relatively low, RNA isolation was performed using RNeasy® Mini Kit 
(Qiagen, Cat No. 74106).  Once removed from -80°C, cell pellets were loosened by 
flicking the tube, and either 350 µl (<5 x 106 ) or 600 µl (5 x 106 – 1 x 107) of Buffer RLT 
was added to the tube.  Cell lysates were homogenized by passing the lysate through a 
21 gauge needle 5-8 times.  One volume 70% ethanol was added to the lysate before 
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transferring 700 µl of the cell suspension to an RNeasy spin column placed in a 
collection tube.  Samples were centrifuged for 15 s at 8000 x g and flow-through 
discarded.  700 µl of Buffer RW1 was added to the column and centrifuged again.  Next, 
the column was washed twice in 500 µl Buffer RPE.  RNA was eluted by adding 30 µl 
RNase-free H2O to the column followed by a 1 min spin at 8000 x g.   
Quantitative Real-Time PCR 
  Our laboratory has previously analyzed BFF cells for Oct-4, Nanog, and Sox-2 
expression, thus we have validated the specificity of primers for PAP, Oct-4, Nanog, 
and Sox-2 (Coley, 2010).  These primers were designed from bovine gene sequences 
using the Beacon Designer 4.0 (PREMIER Biosoft International) (Table 5.1), and were 
diluted to 10 mM concentration.  We extended gene expression analysis to include 
CTNNB1 and EGF in order to assess the specificity of CHIR99021 and PD0325901, 
respectively.  To explore the high incidence of cell death observed in BFF cells treated 
with small molecule inhibitors, BFF cells were also analyzed for the expression of p53, 
which activates the senescent pathway (Sharpless and DePinho, 2002).  In addition to 
PAP, β-actin and GAPDH were used as housekeeping genes for standardization.  The 
qRT-PCR primers used for amplification of these genes have previously been validated 
by others (Table 5.1).  Specificity of the primer sequences was confirmed by 
amplification in calibrator sample.  RNA was amplified using SsoFast™ EvaGreen 
supermix (Bio- Rad Laboratories, Inc., Hercules, CA, USA). The total 20 μl real time  
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Gene 
Accession 
Number 
Primers 
Annealing 
Temp 
Reference 
EGF XM_002696890.2 
Sense  AGTTGGGCACTTTTGAAGACC 
Antisense  
AGGACCACCTCACAGTTGTTG 
 
64° 
(Takatsu et al., 
2015) 
CTNNB1 NM_001076141.1 
Forward  
TGCCCATCTATGAGGGGTACG 
Reverse  
CGCTCCGTGAGGATCTTCATG 
 
60° (Lu et al., 2013) 
P53 U74486 
Sense  CTCAGTCCTCTGCCATACTA 
Antisense  
GGATCCAGGATAAGGTGAGC 
 
50° 
(Matwee et al., 
2000; Favetta et 
al., 2004) 
β-actin BC008633 
Sense  
CGTGACATTAAGGAGAAGCTGTGC 
Antisense  
CTCAGGAGGAGCAATGATCTTGAT 
60° 
(Favetta et al., 
2004) 
GAPDH U85042 
Sense 
CCTTCATTGACCTTCACTACATGGTCTA  
Antisense  
TGGAAGATGGTGATGGCCTTTCCATTG   
60° Adams, 2013 
Table 5.1. Primer sets for qRT-PCR for Gene Expression Analysis 
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PCR mix consisted of 2 μl of cDNA, 10 µl of SsoFast™ EvaGreen Supermix, 6 μl 
of nuclease-free water,  and 1 μl of forward and reverse primer pairs (10 mM) for each 
gene.  All qRT-PCR was performed using Bio-Rad CFX Connect™ Real-Time PCR 
Detection System.  The PCR program used for the amplification of all primers consisted 
of a denaturing cycle of 30 sec at 95°C; 40 cycles of PCR at 95°C for 5 sec and 50-
60°C (primer-specific annealing temperature (Table 5.1) for 20 sec; a melting curve 
analysis which consisted of 95°C for 5 sec, 65°C for 1 min, followed by continuous 
acquisition at 97˚C, with 5 acquistions per ˚C; and a final holding temperature of 4°C. 
Data was quantified using a modified ∆∆Ct  method described by (Hellemans et 
al., 2007).  Values are reported as relative transcription or the n-fold difference relative 
to a calibrator. A mixture of cDNA from BFF cells at multiple passages was used as a 
calibrator for all of the target genes.  The geometric mean of PAP, GAPDH, and β-actin   
was used to normalize data.  Therefore, transcript abundance is calculated relative to 
each reference gene and averaged using the geometric mean. 
Flow Cytometry 
 Flow cytometry was performed using a protocol modified from (Habib et al., 
1999).  On days 7 and 14, both treatment and control cells were harvested by 
trypsinization and washed in 1 ml of PBST-BSA (DPBS without Ca+2 and Mg+2  + 1% 
BSA + 0.1% Tween20).  Cells were counted using a hemacytometer to determine 
concentration of cells in each culture. The cell suspension was then divided evenly 
between two Falcon® 5 mL polystyrene tubes (Cat. No. 352054) to prepare a negative 
autofluorescence control for each sample.  Dissociated cells were then resuspended in 
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2 mL 0.25% paraformaldehyde in DPBS, and allowed to incubate for 10 min at RT for 
cell fixation. Cells were centrifuged at 400 x g for 5 min and resuspended in 200 µl of 
PBS containing 1% BSA (Fraction V).  To detect intracellular molecules, cells were 
permeabilized by slowly adding 1.8 mL of ice-cold methanol to the cell suspension.  
Cells were then incubated for 30 min at -20° C.  Cells were centrifuged at 400 x g for 5 
min at 4°C, methanol discarded, and washed in PBS containing 1% BSA.   Cells were 
incubated in Anti-acetyl-Histone H3, Alexa Fluor® 488 Conjugate (Millipore, Temecula, 
CA, Cat. No. 06-599-AF488) antibody diluted 1:100 in PBS containing 1% BSA for 1 h 
at 4°C.  Equal volume PBS containing 1% BSA was added to the negative 
autofluorescence control tubes.  Afterwards, cells were resuspended in 2 mL PBS 
containing 1% BSA, centrifuged at 400 x g for 5 min, and the supernatant discarded. 
Lastly, cells were resuspended in 300 µl 0.25% paraformaldehyde in DPBS to preserve 
samples for next-day analysis.   
 Flow cytometric analysis was used to quantify global levels of H3ac in cells 
CHIR99021 and PD0325901-indendently and at varying concentrations in combination 
over time.  Samples were assayed on a BD Biosciences FACS Calibur™ (Becton 
Dickinson Immunocytometry Systems, San Jose, CA, USA). Labeled cells were excited 
at 488 nm with a 15-mW argon laser to determine the relative level of acetylated histone 
H3 measured by fluorescence of cells labeled with in Anti-acetyl-Histone H3, Alexa 
Fluor® 488 Conjugate antibody.  Data generated in flow cytometry was analyzed by the 
BD FACStation™ data management system, and the percentage of cells manifesting 
specific fluorescence for the Anti-acetyl-Histone H3, Alexa Fluor® 488 Conjugate 
antibody was calculated.  A negative autofluorescence control for each sample was 
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used to identify forward and side scatter characteristics of the cell population, and 
subsequently used to set PMT voltage and negative gates.    
Statistical Analysis 
 In experiment 1, a completely random design with repeated measures was 
employed to assess any effect treatment with CHIR99021 and PD035901- 
independently and in varying combinations- had on target gene expression in BFF cells 
over time.  The PROC MIXED with repeated measures analysis with autoregression of 
order one covariance was used in SAS statistical software to determine any statistical 
differences in relative gene expression between treatment and control groups over time.  
 In experiment 2, ANOVA to determine variance in relative levels of H3ac 
between control BFF cells and BFF cells treated with CHIR99021 and PD0325901-
indendently and at varying concentrations in combination over time.   
Results 
Gene Expression Analysis 
The values corresponding to the relative expression of Oct-4, Nanog, Sox-2, 
CTNNB1, EGF, and p53 in BFF cells treated in the seven culture systems tested on day 
7 and day 14 are represented in figures 5.1, 5.2, 5.3, and 5.4.  To ensure that 
CHIR99021 and PD0325901 are active in bovine cells under the experimental 
conditions, β-catenin (CTNNB1) and epidermal growth factor (EGF) were used as 
positive control genes.   
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Figure 5.1. Relative expression of Oct-4, Nanog, and Sox-2 in BFF cells 
treated in the following culture systems for 7 days: (1) 3 µM CHIR99021 
(CHIR); (2) 0.5 µM PD0325901 (PD); (3) 3 µM CHIR99021 + 0.5 µM 
PD0325901 (2i); (4) 1.5 µM CHIR9901 + 0.25 µM PD0325901 (2i*); (5) 6 µM 
CHIR99021 + 1 µM PD0325901(2i**); (6) 1 µM Trichostatin A (TSA); (7) 
DMEM + 10% FBS + 1% P/S + 0.053% DMSO (control). Experimental 
procedures were replicated in four different BFF cell lines Target gene 
abundance levels were normalized using the geometric mean of PAP, 
GAPDH, and β-actin. Statistical significance determined as p = 0.05. 
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Figure 5.2. Relative expression of CTNNB1, EGF, and p53 in BFF cells 
treated in the following culture systems for 7 days: (1) 3 µM CHIR99021 
(CHIR); (2) 0.5 µM PD0325901 (PD); (3) 3 µM CHIR99021 + 0.5 µM 
PD0325901 (2i); (4) 1.5 µM CHIR9901 + 0.25 µM PD0325901 (2i*); (5) 6 µM 
CHIR99021 + 1 µM PD0325901(2i**); (6) 1 µM Trichostatin A (TSA); (7) 
DMEM + 10% FBS + 1% P/S + 0.053% DMSO (control). Experimental 
procedures were replicated in four different BFF cell lines Target gene 
abundance levels were normalized using the geometric mean of PAP, 
GAPDH, and β-actin. Statistical significance determined as p = 0.05 and 
indicated by *. 
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treated in the following culture systems for 7 days: (1) 3 µM CHIR99021 
(CHIR); (2) 0.5 µM PD0325901 (PD); (3) 3 µM CHIR99021 + 0.5 µM 
PD0325901 (2i); (4) 1.5 µM CHIR9901 + 0.25 µM PD0325901 (2i*); (5) 6 µM 
CHIR99021 + 1 µM PD0325901(2i**); (6) 1 µM Trichostatin A (TSA); (7) 
DMEM + 10% FBS + 1% P/S + 0.053% DMSO (control). Experimental 
procedures were replicated in four different BFF cell lines Target gene 
abundance levels were normalized using the geometric mean of PAP, 
GAPDH, and β-actin. Statistical significance determined as p = 0.05 and 
indicated by *. 
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Figure 5.3. Relative expression of Oct-4, Nanog, and Sox-2 in BFF cells 
treated in the following culture systems for 14 days: (1) 3 µM CHIR99021 
(CHIR); (2) 0.5 µM PD0325901 (PD); (3) 3 µM CHIR99021 + 0.5 µM 
PD0325901 (2i); (4) 1.5 µM CHIR9901 + 0.25 µM PD0325901 (2i*); (5) 6 µM 
CHIR99021 + 1 µM PD0325901(2i**); (6) 1 µM Trichostatin A (TSA); (7) 
DMEM + 10% FBS + 1% P/S + 0.053% DMSO (control). Experimental 
procedures were replicated in four different BFF cell lines.  Target gene 
abundance levels were normalized using the geometric mean of PAP, 
GAPDH, and β-actin. Statistical significance determined as p = 0.05.   
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Figure 5.4. Relative expression of CTNNB1, EGF, and p53 in BFF cells 
treated in the following culture systems for 14 days: (1) 3 µM CHIR99021 
(CHIR); (2) 0.5 µM PD0325901 (PD); (3) 3 µM CHIR99021 + 0.5 µM 
PD0325901 (2i); (4) 1.5 µM CHIR9901 + 0.25 µM PD0325901 (2i*); (5) 6 µM 
CHIR99021 + 1 µM PD0325901(2i**); (6) 1 µM Trichostatin A (TSA); (7) 
DMEM + 10% FBS + 1% P/S + 0.053% DMSO (control). Experimental 
procedures were replicated in four different BFF cell lines.  Target gene 
abundance levels were normalized using the geometric mean of PAP, 
GAPDH, and β-actin. Statistical significance determined as p = 0.05 and 
indicated by *.   
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CHIR99021 inhibits GSK3 signaling, thus activating Wnt signaling.  CTNNB1 is a major 
downstream component of the Wnt signaling pathway, therefore, its expression is 
interpreted as functional CHIR99021 in our system.  EGF was used as a positive control 
gene for specificity of PD0325901, a MEK/ERK signaling pathway inhibitor.  Consistent 
with the results of 3i treatment, statistical analysis comparing Oct-4, Nanog, and Sox-2 
expression levels in cells treated with CHIR99021 and PD0325901- independently and 
in combination at various concentrations- revealed no significance difference in gene 
expression between groups at either day 7 or day 14.  Conversely, a significant 
difference in p53 expression was observed in 2i** media.  Overall, p53 expression 
increased in culture systems containing CHIR99021 and PD0325901, though not all 
were of statistical significance.  
The components of 2i+ culture medium involve several signaling pathways 
regulating self-renewal and pluripotency. To evaluate the function of these pathways in 
bovine cell types, BFF cells were treated as follows: (1) 3 µM CHIR99021 (CHIR); (2) 
0.5 µM PD0325901 (PD); (3) 3 µM CHIR99021 + 0.5 µM PD0325901 (2i); (4) 1.5 µM 
CHIR9901 + 0.25 µM PD0325901 (2i*); (5) 6 µM CHIR99021 + 1 µM PD0325901(2i**); 
(6) 1 µM Trichostatin A (TSA); (7) DMEM + 10% FBS + 1% P/S + 0.053% DMSO 
(control).  Pictures of cells from each treatment group on days 7 and 14 were captured 
to illustrate the effects of small molecule treatment on cell growth (Figure 5.5 and 5.6).   
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Figure 5.5. BFF cells cultured in (A) 3 µM CHIR99021 (CHIR); (B) 0.5 µM 
PD0325901 (PD); (C) 3 µM CHIR99021 + 0.5 µM PD0325901 (2i); (D) 1.5 
µM CHIR9901 + 0.25 µM PD0325901 (2i*); (E) 6 µM CHIR99021 + 1 µM 
PD0325901(2i**); (F) DMEM + 10% FBS + 1% P/S + 0.053% DMSO; (G) 1 
µM Trichostatin A (TSA) for 7 days 
 
Figure 5.5. BFF cells cultured in (A) 3 µM CHIR99021 (CHIR); (B) 0.5 µM 
PD0325901 (PD); (C) 3 µM CHIR99021 + 0.5 µM PD0325901 (2i); (D) 1.5 
µM CHIR9901 + 0.25 µM PD0325901 (2i*); (E) 6 µM CHIR99021 + 1 µM 
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Figure 5.6. BFF cells cultured in (A) 3 µM CHIR99021 (CHIR); (B) 0.5 µM 
PD0325901 (PD); (C) 3 µM CHIR99021 + 0.5 µM PD0325901 (2i); (D) 1.5 
µM CHIR9901 + 0.25 µM PD0325901 (2i*); (E) 6 µM CHIR99021 + 1 µM 
PD0325901(2i**); (F) DMEM + 10% FBS + 1% P/S + 0.053% DMSO; (G) 1 
µM Trichostatin A (TSA); for 14 days. 
 
Figure 5.6. BFF cells cultured in (A) 3 µM CHIR99021 (CHIR); (B) 0.5 µM 
PD0325901 (PD); (C) 3 µM CHIR99021 + 0.5 µM PD0325901 (2i); (D) 1.5 
µM CHIR9901 + 0.25 µM PD0325901 (2i*); (E) 6 µM CHIR99021 + 1 µM 
PD0325901(2i**); (F) DMEM + 10% FBS + 1% P/S + 0.053% DMSO; (G) 1 
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Noticeable differences in cell morphology and growth can be seen between 
culture groups over time.  Notably, cells treated with PD, 2i, and 2i** exhibit reduced cell 
growth in culture compared to the other groups.  This observation correlates to the 
population doublings calculated at day 7 and day 14, which show a reduction in cell 
concentration (Table 5.2).   All cells were seeding at a density of 0.3 x 106  into 6 well 
plates.  On days 7 and 14 cells were harvested for downstream applications, and the 
cells were counted.  The population doublings for DMSO treated cells were consistent 
with BFF cell growth in culture (Giraldo et al., 2009).  The counts at the time of harvest 
for PD, 2i, 2i*, and 2i** treated cells were all either reduced or approximately the same 
as the seeding density.  CHIR treated populations increased to approximately ~0.5 x106 
cells at the time of harvest, but still lower than what is anticipated for BFF cells under 
normal culture conditions.  This illustrates the difficulty in growing cells to a sufficient 
quantity for subsequent use as donor cells for NT in the presence of these small 
molecule inhibitors.  
Flow Cytometric Analysis of Histone H3 Acetylation 
 Flow cytometric analysis was performed on cell populations treated under seven 
culture conditions (CHIR; PD; 2i; 2i*; 2i**; TSA, DMSO) for 7 days and 14 days to 
determine global H3ac levels (Figure 5.7 and 5.8).  The experiment was performed on 
four BFF cell lines, and the mean percent of positive values generated for H3ac is 
reported in Table 5.3.  Treatment with Trichostatin A (TSA) was used as a positive 
control for our experimental designs.  TSA is a member of the subgroup of HDAC 
inhibitors that induce tubulin hyperacetylation.  Therefore, an increased amount of H3ac  
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Culture Medium Day 7 Day14 
CHIR 0.83 0.56 
PD -0.60 -0.60 
2i 0.40 0.20 
2i* -0.27 -0.17 
2i** -0.90 -1.26 
DMSO 1.53 1.94 
TSA 0.94 0.78 
Table 5.2. Population doubling of BFF cells after 7 and 
14 days of treatment in culture media 
 
Table 5.2. Population doubling of BFF cells after 7 and 
14 days of treatment in culture media 
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Figure 5.7. Histograms representing the percentage of positive cells for 
Histone H3 Acetylation in CHIR99021 and PD0325901 in BFF cells 
cultured in (A) 3 µM CHIR99021 (CHIR); (B) 0.5 µM PD0325901 (PD); (C) 
3 µM CHIR99021 + 0.5 µM PD0325901 (2i); (D) 1.5 µM CHIR9901 + 0.25 
µM PD0325901 (2i*); (E) 6 µM CHIR99021 + 1 µM PD0325901(2i**); (F) 
DMEM + 10% FBS + 1% P/S + 0.053% DMSO; (G) 1 µM Trichostatin A 
(TSA) after 7 days. 
 
Figure 5.7. Histograms representing the percentage of positive cells for 
Histone H3 Acetylation in CHIR99021 and PD0325901 in BFF cells 
cultured in (A) 3 µM CHIR99021 (CHIR); (B) 0.5 µM PD0325901 (PD); (C) 
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Figure 5.8. Histograms representing the percentage of positive cells for 
Histone H3 Acetylation in CHIR99021 and PD0325901 in BFF cells 
cultured in (A) 3 µM CHIR99021 (CHIR); (B) 0.5 µM PD0325901 (PD); (C) 
3 µM CHIR99021 + 0.5 µM PD0325901 (2i); (D) 1.5 µM CHIR9901 + 0.25 
µM PD0325901 (2i*); (E) 6 µM CHIR99021 + 1 µM PD0325901(2i**); (F) 
DMEM + 10% FBS + 1% P/S + 0.053% DMSO; (G) 1 µM Trichostatin A 
(TSA) after 14 days. 
 
Figure 5.8. Histograms representing the percentage of positive cells for 
Histone H3 Acetylation in CHIR99021 and PD0325901 in BFF cells 
cultured in (A) 3 µM CHIR99021 (CHIR); (B) 0.5 µM PD0325901 (PD); (C) 
3 µM CHIR99021 + 0.5 µM PD0325901 (2i); (D) 1.5 µM CHIR9901 + 0.25 
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in cells cultured in TSA demonstrates that the flow cytometric techniques used in this 
experiment are sufficiently specific and sensitive to detect changes in levels of 
acetylated histone H3 compared to those induced by this chemical. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Culture 
Medium 
Mean % 
Positive Cells 
D7 
Mean % 
Positive Cells 
D14 
CHIR 77.0% 93.5% 
PD 80.7% 81.4% 
2i 77.1% 80.4% 
2i* 72.7% 78.6% 
2i** 72.9% 83.3% 
TSA 78.1% 91.9% 
DMSO 4.0% 3.86% 
Table 5.3. Percentage of Positive Cells for Histone H3 
Acetylation in CHIR99021 and PD0325901 Culture 
Systems at Days 7 and 14 
 
Table 5.3. Percentage of Positive Cells for Histone H3 
Acetylation in CHIR99021 and PD0325901 Culture 
Systems at Days 7 and 14 
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Discussion 
Senescence represents an reversible state at the G1 phase of the cell cycle that 
is induced by replicative exhaustion or in response to stress on the cell.  Several factors 
may contribute to the induction of apoptosis in cells reprogrammed towards 
pluripotency, including the level of reactive oxygen species (ROS). High ROS levels 
promote the modification of individual nucleotide bases, the formation of single and 
double strand breaks, and leads to telomere shortening, all of which results in the 
activation of p53 (Sharpless and DePinho, 2002; Favetta et al., 2004; Hong et al., 
2009).  Studies in PD0325901 have shown that PD0325901 significantly inhibited the 
growth of PTC cells harboring a BRAF mutation at very low concentration (10 nmol/L).  
They determine the mechanism of growth inhibition to be caspase 3, indicative of 
apoptosis (Henderson et al., 2010).   
Recent studies suggest that p53 recognizes short and damaged telomeres, 
activating the senescent pathway.  Furthermore, loss of p53 function reduces the signs 
of aging irrespectively of telomere length, suggesting the role for p53 rather than 
telomeres in the induction of cellular senescence.  In mouse and human diploid 
fibroblast, downregulation of p53 expression extends their in vitro life span and leads to 
rapid cell cycle re-entry.  In vitro studies in mice also indicate that senescence is caused 
by the activation of a p53-dependent  cell cycle checkpoint that prevents cell 
proliferation.  The p53 tumor suppressor protein is a potent transcription factor that can 
transactivate genes involved in both growth arrest and apoptosis (Helleman et al., 2011; 
Henderson et al., 2010).  It is important to remember that the usefulness of quiescent 
cells has been attributed to their reduced transcriptional activity and chromatin 
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modifications that are associated with cells in G0, which may enhance their epigenetic 
plasticity (Armstrong et al., 2006). 
These findings and ours are in support to those of Tsutsui et al (2011).  They 
concluded that he key effect of CHIR99021 therefore does not involve the induction of 
Nanog. Because Nanog-overexpressing ES cells are independently blocked in 
differentiation, this result further suggests that the contribution of GSK3 inhibition 
extends beyond limiting differentiation. To probe this further, they evaluated whether 
CHIR99021 could rescue ESC subjected to a more profound blockade of phospho-ERK. 
A higher dose of PD0325901 (2 or 3 μM) almost entirely eliminates phospho-ERK and 
causes growth arrest and cell death. The addition of CHIR99021 restores viability and 
allows efficient expansion of undifferentiated ES cells in the near absence of ERK 
signaling.  Therefore, as phospho-ERK is diminished, down modulation of GSK3 
becomes increasingly crucial to maintain metabolic activity, biosynthetic capacity and 
overall viability.  Tsutsui et al., 2011 concluded that the pivotal contribution of GSK3 
inhibition is to restore full growth and viability. This may be achieved by balancing the 
loss of ERK input into basic cellular processes.  Additionally, they did not detect any 
apoptotic activity with CHIR999021, consistent with our findings as well.   
Further investigation into the actual cause of the observed cell growth inhibition 
be it apoptosis or quiescence should be investigated.  More sensitive techniques that 
probe the actual cause of this observation, such as click-iT® TUNEL Alexa Fluor 
Imaging Assay (Cat. No. C110246; Invitrogen) used by Huang et al., 2011 to detect 
apoptosis in experimental cell lines.  Similarly, Huang and colleagues (2011) used the 
the RTCA-SP CELLigence system (Roche) to better characterize the response of 
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bovine cells to comparable murine and human cells.  Notably, they detected a 
significant difference in proliferation, viability, morphology, and adhesion.  By pinpointing 
whether these cells are entering quiescence or apoptosis as a result of treatment, as 
well as, species-specific response to treatment, researchers should be able to 
manipulate their reprogramming mechanism to induce a stably reprogrammed cell line 
for use in SCNT procedures specific for the species of interest.  It should also be noted 
that while the increase in p53 expression seems contradictory to the increase in H3ac, it 
has been well noted that quiescent cells are easier to reprogram (Wells et al., 2013), 
suggesting that this data actually work in support of one another.  It is important to note 
that very new studies suggest a strong genetic correlation to reprogramming ability 
(Atkinson et al., 2018). This is in support of the findings of this study, suggesting that the 
bovine may indeed be different than its human and murine counterpart, which may 
ultimately affect its ability to reprogram to a sufficient quanta of cells suitable for 
downstream applications such as SCNT.   While it appears that the bovine is reliant on 
the same signaling pathways as the mouse and human for nuclear reprogramming, the 
mechanism of action in doing so may not be as effective as it is in their human and 
murine counterparts.  Alternatives to PD0325901 should be explored to see their 
effectiveness in the bovine.   
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CHAPTER VI 
SUMMARY AND CONCLUSIONS 
 
In 2006, Takahashi and Yamanaka reported the generation of a population of 
cells similar to ESC by transfecting mouse tail fibroblast cells with four transcription 
factor-encoding genes.  These cells, termed induced pluripotent stem cells (iPSC), are 
believed to be immensely beneficial in the study and treatment of disease as the direct 
reprogramming of somatic cells provides an opportunity to generate patient- or disease-
specific pluripotent stem cells (Nakagawa et al., 2008).  The supposed potential of iPSC 
lies in the fact that these cells are morphologically similar to pluripotent ESC and, most 
importantly, demonstrate key characteristics of pluripotent ESC, including expressing 
stem cell markers, forming teratomas containing cells of all three germ layers, and 
contributing to multiple cell lineages (Takahashi and Yamanaka, 2006).  This landmark 
discovery has opened a new frontier in the field of regenerative medicine because, for 
the first time, a realistic way of generating sufficient numbers of patient-specific 
pluripotent stem cells exists (Amabile and Meissner, 2009).  Furthermore, this method 
of generating iPSC has provided researchers with a new and unique tool to study 
mammalian development and the mechanisms underlying nuclear reprogramming.  The 
breakthrough discovery that lineage-restricted somatic cells can be reprogrammed to a 
pluripotent state through the ectopic expression of defined transcription factors 
represents the culmination of over 50 years of research, and there is no sign of 
research slowing down anytime soon.   
Considering the many advantages of a chemical approach to nuclear 
reprogramming, we first assessed the effect of pre-treatment with small molecule 
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inhibitors on the expression of Oct-4, Nanog, and Sox-2 in BFF cells. The small 
molecule inhibitors, CHIR99021 and PD325901, have been widely used as tools to 
facilitate the generation and maintenance of iPSC (Li et al., 2009; Lin et al., 2009; 
Hanna et al., 2010; Zhou et al., 2010).  In these cases, CHIR99021 and PD325901 aid 
in overcoming the “roadblocks” encountered during the reprogramming process by 
inducing the necessary epigenetic modifications needed to silence the somatic cell 
genome and completely reactivate the ESC genome.  We have previously shown that 
some sources of ASC, including BFF, express transcripts for the key pluripotency 
genes, Oct-4, Nanog, and Sox-2 (Coley, 2007).  While these cell types’ differentiating 
and self-renewing capabilities are far less robust than that of ESC, we reasoned that the 
same system involved in promoting the pluripotent state in mESC and hESC would 
similarly work to maintain, or possibly enhance, the less differentiated state 
characteristic of BFF cells.  While there was no significant increase in Oct-4, Nanog, or 
Sox-2 relative gene expression detected between control and treatment samples at 
either day 7 or day 14, it is important to note that there was no significant decrease in 
the relative expression of these transcripts over time either.  Typically, pluripotent gene 
expression in ASC decreases as passage number increases (Tsai and Hung, 2012), yet 
the extended culture period and consequential passaging required to maintain cells in 
culture for an extended period of time did not result in a significant decrease in Oct-4, 
Nanog, or Sox-2 expression.   
Expanding on our study and the evidence that small molecule compounds that 
target chromatin modifications and/or specific signaling pathways have proven to be 
effective at overcoming reprogramming hurdles, we next sought to assess the effects of 
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pre-treatment with the small molecules CHIR99021, PD325901, and NuP0178 on the 
methylation status of H3K4, H3K9, and H3K27 at the promoter regions of the key 
pluripotency-associated genes, Oct-4, Nanog, and Sox-2.  To examine the effect of 3i 
treatment on histone methylation at the lysine 4, 9, and 27 residues in Oct-4, Nanog, 
and Sox-2, we utilized ChIP, a powerful and popular tool for understanding the 
mechanisms of gene regulation by transcription factors and modified histones.  Using 
antibodies that recognize a specific protein or protein modification of interest, ChIP 
determines the relative abundance of that protein or protein modification of interest at 
one or more locations in the genome.  ChIP is the most widely used procedure for the 
examination of histone modification, and it has proven to yield very valuable information 
on chromatin-associated processes in numerous species.  Nevertheless, the technique 
must be optimized by each investigator in their model system specific.  Optimization of 
cell harvesting, the cross-linking of chromatin, sonication conditions, and qRT-PCR 
setup and analysis of ChIP-enriched genomic DNA is very tedious, challenging, and 
time-consuming.  Indeed, this proved to be true for this research project.  Nevertheless, 
our laboratory has successfully created a working protocol for performing ChIP on BFF 
cells subjected to pre-treatment with the small molecule inhibitors, CHIR99021, 
PD325901, and NuP0178. 
 Perhaps the greatest hurdle presented in this research project, and consequently 
the greatest limitation of widespread implementation of the treatment with this 
combination of small molecules, is that many cells do not survive treatment.  
Maintaining BFF cells treated with 3i+ media for the duration of 14 days was extremely 
hard to do.  Because of the extraordinarily high rate of cell death attributed to chemical 
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treatment, it was extremely difficult to harvest enough cells and subsequent chromatin 
required to perform ChIP.  Despite countless attempts to carry out this experiment, our 
laboratory was only successful at generating samples with a sufficient amount of 
chromatin for ChIP a handful of times, making it difficult to statistically analyze our 
results and draw any significant conclusions.  While the results we obtained from this 
research are interesting, there are likely better, more efficient means of chemically-
induced nuclear reprogramming.  That being said, one way to improve to overall 
survival of cells following induction to reprogram towards pluripotency may be the use of 
antioxidants in culture systems.  Several groups have reported success following 
inhibitory ROS exposure using antioxidants such as Vitamin C (Huangfu et al., 2008; 
Zhong-Dong Sui et al., 2016).  Furthermore, the degree of variability in the effectiveness 
of treatment and the resulting outcome is, in our opinion, another great hindrance to the 
widespread application of this combination of small molecule inhibitors for priming BFF 
cells for nuclear reprogramming.  We believed that the high variability in Oct-4, Nanog, 
and Sox-2 relative gene expression, as well as H3K4me3, H3K9me3, H3K27me3 we 
observed in BFF cells makes their response to pre-treatment with CHIR99021, 
PD325901, and NuP0178 unpredictable in addition to being inefficient.  
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APPENDIX A: PROTOCOLS 
DYNABEADS® RNA ISOLATION PROTOCOL 
1. Harvest cells from culture flask as per standard procedure 
2. Wash cell pellet first in 1 ml of PBS with Ca+2 and Mg+2  and then in 300 µl of 
lysis/binding buffer (100mM Tris HCl (pH 8.0), 500 mM LiCl, 10 mM EDTA, 1% 
lithium dodecylsulfate, and 5 mM dithiothreitol) 
3. Strip cells using a 21 gauge needle and a 1 ml syringe.  Vortex for 10 sec. 
4. Centrifuge at 12000 x g for 15 sec. and incubate at RT for 10 min. 
5. Add 50 µl of the pre-washed oligo dT Dynabeads (dT25) to the tube (pre-washed 
Dynabeads in lysis/binding buffer) 
6. Incubate at RT for 10 min in hybridization mixer 
7. Place tube in magnetic separator for 2 min 
8. Remove supernatant and wash beads twice in 50 µl of Buffer A (10 mM Tris HCl 
(pH 8.0), 150 mM LiCl, 1 mM EDTA, 0.1% lithium dodecylsulfate) and twice in  
50 µl of Buffer B (10 mM Tris HCl (pH 8.0), 150 mM LiCl, 1 mM EDTA). 
9. Elute RNA from the beads by adding 15µL of nuclease-free water and heating 
the sample at 70˚C for 2 min. 
10.   Use sample directly for reverse transcription  
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cDNA SYNTHESIS PROTOCOL 
1. Mix 4 µl of iScript reaction mix, 1 µl of reverse transcriptase, and 15 µl of sample 
mRNA in PCR tube (Bio-Rad Laboratories, Inc., Hercules, CA, USA)  
2. Place tubes in the thermocycler and run for 5 min at 25˚C, 30 min at 42˚C, 
denaturation at 85˚C for 5 min, and a final hold at 4˚C. 
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qRT-PCR PROTOCOL FOR GENE EXPRESSION ANALYSIS 
1. Prepare master mixes for each gene being analyzed (Oct-4, Nanog, Sox-2, 
PAP).  Each reaction contains 10 µl of SsoFast™ EvaGreen supermix (Bio-Rad 
Laboratories, Inc., Hercules, CA, USA), 6 µl of nuclease-free water, 1 ul of each 
[10 mM] primer (sense and antisense), and 2 µl of either sample or calibrator 
cDNA (added later).   
2. Pipette 18 µl of the appropriate master mix into the designated wells of a 96 
multiwell plate tailor-made for Bio-Rad CFX Connect™ Real-Time PCR Detection 
System. 
3. Add 2 µl of either sample or calibrator cDNA to each designated well 
4. Cover plate with sealing foil 
5. Place plate in the Bio-Rad CFX Connect™ instrument and run a denaturing cycle 
of 30 sec at 95°C; 45 cycles of PCR (95°C for 5 sec and 55°C for 20 sec); a 
melting curve analysis which consisted of 95°C for 5 sec, 65°C for 1 min, 
followed by continuous acquisition at 97˚C, with 5 acquistions per ˚C; and a final 
holding temperature of 40°C.  
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qRT-PCR PROTOCOL FOR ANALYSIS OF CHIP 
1. Set up PCR reactions for the following templates: DNA from ChIP samples with 
test antibodies (H3K4me3, H3K9me3, H3K27me3), Input DNA samples, and 
DNA from ChIP performed with the negative control antibody (No Ab). Run PCR 
in duplicates.  
2. Prepare master mixes for each gene being analyzed for ChIP (Oct-4, Nanog, and 
Sox-2).   Each reaction contains 10 µl of SsoFast™ EvaGreen supermix (Bio-Rad 
Laboratories, Inc., Hercules, CA, USA), 6 µl of nuclease-free water, 1 ul of each 
[10 mM] primer (sense and antisense), and 2 µl of sample DNA. 
3. For each PCR reaction, add 5 µl of sample DNA to 45 µl of the appropriate gene 
master mix.  
4. Pipette 20 µl of the sample DNA + gene mix into the designated wells of a 96 
multiwell plate tailor-made for Bio-Rad CFX Connect™ Real-Time PCR Detection 
System.  Repeat this so that PCR is run in duplicates. 
5. Cover plate with sealing foil 
6. Place plate in the Bio-Rad CFX Connect™ instrument and run a denaturing cycle 
of 2 min at 94°C; 40 cycles of PCR (94°C for 30 sec and 52°C for 40 sec, 72°C 
for 30 sec); followed by final extension 72˚C for 7 min.  
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CHROMATIN IMMUNOPRECIPITATION PROTOCOL OPTIMIZED FOR 3i-TREATED 
BFF CELLS USING ChIP-IT® EXPRESS MAGNETIC CHROMATIN 
IMMUNOPRECIPITATION KIT (Active Motif 53008) 
Cell Fixation and Shearing 
 
1. When cells are ready to harvest, freshly prepare the appropriate volume of 
Fixation Solution and 1X PBS Solution based on number of cells 
2. Harvest cells by trypsinization per standard protocol.  If cells were grown in 
multiple T-25 flasks, samples can be pooled at this time 
3. Centrifuge 300 x g for 5 min  
4. Discard supernatant and resuspend pellet in 5 mL of Fixation Solution 
5. Incubate for 10 min at RT 
6. Add 500 µL of 10X Glycine directly to cell suspension and mix to stop the fixation 
(100 µL 10X Glycine per 1 mL of Fixation Solution) 
7. Centrifuge 300 x g for 5 min 
8. Wash cells in 5 mL of ice-cold 1X PBS Solution 
9. Discard supernatant and add 1 µL PIC and 1 µL PMSF to cell pellet.  Store at      
-80°C 
Shearing by Sonication 
1. Thaw previously frozen cell pellet on ice and resuspend in 500 µL ice-cold Lysis 
Buffer supplemented with 2.5 µL PIC and 2.5 µL PMSF.  Incubate on ice for 30 
min 
2. Transfer cell suspension to dounce homogenizer.  Dounce on ice with 40-50 
strokes to aid in nuclei release.  Use a phase contrast microscope to monitor cell 
lysis after every 10 strokes to verify that the nuclei have been released 
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3. Transfer lysate to 1.7 mL microcentrifuge tube and centrifuge 2,400 x g for 10 
min at 4°C 
4. Carefully discard supernatant and resuspend in 300 µL Shearing Buffer 
supplemented with 1.5 µL PIC and 1.5 µL PMSF 
5. Place tube in a rack holder and pack on ice, ensuring the tube is surrounded by 
ice 
6. Shear DNA by sonication with a Cole Palmer Ultrasonic Processor (Cole-Palmer, 
Vernon Hills, IL USA) (500 watts, 120 volts, 3 mm probe) using the conditions 
determined to provide optimally sheared chromatin for BFF cells in this 
experiment (25 pulses of 20 sec, 30 sec rest). 
7. Centrifuge 14,000 x g for 10 min at 4°C in a microcentrifuge 
8. Very carefully transfer the supernatant, which contains the sheared chromatin, to 
a new 1.7 mL microcentrifuge tube 
9. Prepare 50 µL aliquots of sheared chromatin.  One 50 µL sample will be used 
immediately for assessing the efficiency of DNA shearing and determining the 
DNA concentration.  Store the remaining 50 µL aliquots of sheared chromatin at -
80°C 
DNA Cleanup to Assess Shearing Efficiency and DNA Concentration 
1. Add 150 µL dH2O and 10 µL 5 M NaCl to the sheared chromatin sample 
2. Incubate tubes overnight at 65°C in thermocycler to reverse the cross-links 
3. Following incubation, add 1 µL RNase A to each sample and incubate at 37°C for 
15 min 
4. Add 10 µL Proteinase K to each sample and incubate at 42°C for 1.5 h 
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5. Add 200 µL 1:1: Phenol/Chloroform TE saturated pH8 (Sigma Aldrich, P3803) to 
each tube and vortex to mix thoroughly 
6. Centrifuge 14,000 x g for 5 min 
7. Transfer the aqueous phase to a fresh microcentrifuge tube, then add 20 µL 3 M 
Sodium Acetate pH 5.2 followed by 500 µL 100% ethanol.  Lastly, add 1 µL 
Glycogen (20 µg/µL) to aid in recovery of a visible pellet following precipitation  
8. Incubate sample at -20°C overnight 
9. The next day, centrifuge sample 14,000 x g for 10 min at 4°C in microcentrifuge 
10. Carefully remove and discard the supernatant, leaving the pellet undisturbed 
11. Add 500 µL 70% ice cold ethanol to the tube without disturbing the pellet and 
centrifuge 14,000 x g for 5 min at 4°C 
12. Remove and discard supernatant, careful not to disturb the pellet.  Allow pellet to 
air-dry under hood 
13. Once dry, resuspend the pellet in 30 µL dH20 
14. Determine the DNA concentration of the sheared sample using a 
spectrophotometer 
15. To assess the efficiency of sonication, add 4 µL of a 6X Loading Buffer Dye to 16 
µL of sheared chromatin.  Load both 5 µL and 10 µL of sample on a 1% agarose 
gel and run at 100V for approximately 45 min.  Optimal shearing by sonication 
yields a smear between 200-1500 bp.   
Immunoprecipitation 
1. If necessary, thaw 50 µL aliquot of chromatin on ice.  Transfer 10 µL of chromatin 
to a microcentrifuge tube and set aside.  This is the “Input DNA”, which will be 
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processed later and used as a control in PCR analysis.  Store at 4° C if it will be 
used within 6 h; otherwise, store at -20° C. 
2. Set up the ChIP reactions by adding the components shown in the table below to 
the provided siliconized 1.7 microcentrifuge tubes.  Use the DNA concentration 
that was determined for the sheared chromatin sample to calculate the volume of 
chromatin to use.  Resuspend the magnetic beads by inverting and/or vortexing 
the tube before use.  The antibody should be the final component added to the 
reaction. 
Reagent One Reaction (if using 
less than 60 µL of 
chromatin) 
One Reaction (if using 
more than 60 µL of 
chromatin) 
Protein G Magnetic 
Beads 
25 µL 25 µL 
ChIP Buffer 1 10 µL 20 µL 
Sheared Chromatin (7-
25 µg) 
20-60 µL 61-100 µL 
PIC 1 µL 2 µL 
dH2O Add enough so that final 
volume of reaction is 
100 µL 
Add enough so that final 
volume of reaction is 
200 µL 
Antibody 1-3 µg 1-3 µg 
Total Volume 100 µL 200 µL 
 
3. Cap the tube and incubate overnight at 4° C on an end-to-end rotator. 
4. Following incubation, spin the tube briefly to collect liquid from inside the cap. 
5. Place tube on magnetic stand to pellet the beads on side of the tube. 
6. Carefully remove and discard the supernatant. 
Wash Magnetic Beads 
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1. Wash beads 1X with 800 µL of ChIP Buffer 1. 
2. Wash beads 2X with 800 µL of ChIP Buffer 2.  Allow no more than 1 min to 
elapse between removing buffer and adding the next wash. 
3. After the final wash, remove as much supernatant as possible without disturbing 
the beads. 
Elute Chromatin, Reverse Cross-links, and Treat with Proteinase K 
1. Resuspend the washed beads in 50 µL Elution Buffer AM2, careful not to allow 
more than 1 min to elapse between removing ChIP Buffer 2 and adding the 
elution buffer. 
2. Place the tube on an end-to-end rotator and incubate for 15 min at RT. 
3. Briefly spin the tube to collect liquid from the cap. 
4. Add 50 µL Reverse Cross-linking Buffer to the eluted chromatin and mix by 
pipetting up and down.  Place tube in magnetic stand, and all the beads to pellet 
to the side of the tube. 
5. Transfer the supernatant, which contains the chromatin, to a fresh tube. 
6. Now, process the “Input DNA” by taking the 10 µL of chromatin that was set 
aside earlier and thaw on ice, if necessary.  Add 88 µL ChIP Buffer 2 and 2 µL 
5M NaCl to the Input DNA sample, so that the final volume is 100 µL. 
7. Incubate both the Input DNA and ChIP samples at 95° C for 15 min in a 
thermocycler. 
8. Remove the tubes from the thermocycler, allowing them to return to RT.  Briefly 
spin the tubes if liquid has collected in the caps.  Then, add 2 µL Proteinase K to 
each tube. 
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9. Mix well and incubate the tubes at 37° C for 1 h.  During this time, remove the 
Proteinase K Stop Solution from the freezer, and allow it to sit at RT for 30 min to 
1 h. 
10.  After incubation, allow the tubes to return to RT.  Then, add 2 µL Proteinase K 
Stop Solution to each tube.  Briefly centrifuge the tubes to collect any liquid from 
the caps.  Immediately proceed with the DNA purification procedure, or store at -
20° C until ready. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
145 
 
CHROMATIN IP DNA PURIFICATION USING CHROMATIN IP DNA PURIFICATION 
KIT (Active Motif 58002) 
Purification of DNA from Chromatin IP Samples 
1. If necessary, transfer ChIP samples to an Eppendorf tube, and add 5 volumes 
DNA Purification Binding Buffer for every one volume of sample DNA.  
2. Add 5 µL 3M Sodium Acetate to each tube and mix.  Check that the color of the 
DNA sample/DNA Purification Binding Buffer mixture is bright yellow, not light 
orange or violet.  If it is light orange or violet, adjust the pH by adding more 3M 
Sodium Acetate- 5 µl at a time- until it is bright yellow in color.   
3. For each sample, place a DNA purification column in the collection tube and add 
each sample to its own column.  Close the cap on each column, place them with 
the collection tubes in a microcentrifuge, and spin 14,000 x g for 1 min at RT. 
4. Remove the column from the collection tube, then remove and discard the flow-
through from the collection tube.   
5. Return the column to the collection tube, and add 750 µl 80% DNA Purification 
Wash Buffer (reconstituted with 100% ethanol) to the column.   
6. Cap the column and centrifuge 14,000 x g for 1 min at RT. 
7. Remove the column from the collection tube, then remove and discard the flow-
through from the collection tube.  
8. Return the column to the collection tube.  With the column caps open, centrifuge 
again 14,000 x g for 2 min at RT to remove any residual DNA Purification Wash 
Buffer from the column. Discard the collection tube.  
9. Transfer the column to a fresh Eppendorf tube, and add 50 µl DNA Purification 
Elution Buffer to the center of the column matrix.  Wait for 1 min. 
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10.  After 1 min, centrifuge the column with the collection tube 14,000 x g for 1 min at 
RT. 
11.  Discard the column.  The DNA eluted into the Eppendorf tube is purified and 
ready to be used in PCR.  
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APPENDIX B: MEDIA FORMULATIONS AND STOCK SOLUTIONS 
Complete Culture Medium 
DMEM 
10% FBS 
1% P/S 
3i+ Medium 
DMEM 
10% FBS 
1% P/S 
0.5 µM PD0325901 
3 µM CHIR99021 
1.8 µM NuP0178 
Fixation Solution 
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